PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16839691-2	2006	Therefore, the aim of the present study was to examine the role of endogenous and exogenous ovarian steroids in the induction of perseverative responses in a T-maze by the 5-HT1A agonist 8-OH-DPAT (1.0 and 2.0 mg/kg, SC) and in the preventive action of the selective serotonin reuptake inhibitor, fluoxetine (10.0 mg/kg, three times, SC).	8-Hydroxy-2-(di-n-propylamino)tetralin	187-196	5-hydroxytryptamine receptor 1A	Homo sapiens	172-178	
16452654-7	2006	Paradoxically, systemic administration of the 5-HT1a agonist 8-OH-DPAT also attenuated LTP.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	46-52	
16447179-4	2006	The purpose of this work is to determine the specific binding sites using [(3)H]8-hydroxy-2(di-n-propylamino)tetralin ([(3)H]8-OH-DPAT), a specific agonist of the 5-HT(1A) receptor, and to characterize the diurnal rhythm in the binding by an autoradiography procedure in the crayfish ES.	8-Hydroxy-2-(di-n-propylamino)tetralin	124-134	5-hydroxytryptamine receptor 1A	Homo sapiens	163-180	
16730359-6	2006	The inhibition of the synthesis of 5-HT by p-chlorophenylalanine and the pre-administration of the 5-HT(1A) receptor agonist, 8-OH-DPAT at 40microg/kg, caused a significant potentiation of the tramadol effect decreasing the ED(50) by 53% and 67% respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Homo sapiens	99-116	
15152026-1	2004	The serotonin (5-hydroxytryptamine1A) 5-HT1A receptor agonist 8-OH-DPAT [(R)- (+)-8-hydroxy-2-(di-n-propylamino)tetralin] inhibits bladder activity under nociceptive but not innocuous conditions in cats with an intact spinal cord, suggestive of an effect on primary afferent C fibers or their targets.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44	
15829255-2	2005	Pre-training administration of the 5-HT1A receptor agonist 8-OH-DPAT impaired WM performance and facilitated PA retention at low doses (0.01 and 0.03 mg/kg) and impaired PA retention at higher doses (0.1-1.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	35-50	
15721170-4	2005	The 5-HT(1A) agonists 8-OH-DPAT and buspirone mimic the effect of 5-HT, whereas the selective 5-HT(1A) receptor antagonist WAY-100635 (1 microM) significantly prevents the effect of 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	22-31	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11	
15364487-4	2004	or s.c.) after training, significantly decreased the improvement of performance produced by the 5-HT(1A/7) agonist 8-OH-DPAT to levels lower than controls".	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Homo sapiens	96-103	
15482641-1	2004	Twenty agonists and nine antagonists were evaluated for their ability to compete for [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) binding to the cloned human serotonin-1A (ch-5-HT1A) receptor expressed in Chinese hamster ovary cells and for their ability to alter adenylyl cyclase activity in the same cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-128	5-hydroxytryptamine receptor 1A	Homo sapiens	191-207	
15482641-1	2004	Twenty agonists and nine antagonists were evaluated for their ability to compete for [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT) binding to the cloned human serotonin-1A (ch-5-HT1A) receptor expressed in Chinese hamster ovary cells and for their ability to alter adenylyl cyclase activity in the same cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Homo sapiens	191-207	
15234111-4	2004	Moreover, the 5-HT(1A) receptor agonist 8-OH-DPAT (1 microM) mimicked the 5-HT effect.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	14-31	
16081165-4	2005	Apoptotic and non-apoptotic fetal rhombencephalic neurons were quantitated in primary cultures that were treated with 50 mM ethanol and with 100 nM of a 5-HT1A agonist such as 8-OH-DPAT [8-hydroxy 2-(di-n-propylamino)tetralin], ipsapirone, or buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Homo sapiens	153-159	
16148240-5	2005	We analyzed sleep before and after unilaterally dialyzing the 5-HT1A agonist (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) into the juxtafacial PGCL in conscious newborn piglets.	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Homo sapiens	62-68	
16148240-8	2005	The effects of 8-OH-DPAT were blocked by local pretreatment with N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexane-carboxamide, a selective 5-HT1A antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Homo sapiens	162-168	
15722055-6	2005	Pretreatment with local injections of p-MPPI (an antagonist of 5-HT1A receptors) attenuated the ingestive responses evoked by 8-OH-DPAT injections.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69	
15469667-5	2004	5-HT1A receptor binding was assayed in post-mortem prefrontal cortex using [3H]8-OH-DPAT, and specific binding determined by 1 microM 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15	
15190115-2	2004	We have demonstrated previously, using immunoelectron microscopy with specific 5-HT1A antibodies, that an internalization of 5-HT1A autoreceptors is associated with their desensitization in rats given a single dose of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	246-284	5-hydroxytryptamine receptor 1A	Homo sapiens	125-131	
15628665-4	2004	We report here the pharmacological characterization of one of the first isolated clones of CHO cells stably expressing the human 5-HT1A receptor using the selective agonist 8-OH-DPAT and antagonist p-MPPF.	8-Hydroxy-2-(di-n-propylamino)tetralin	173-182	5-hydroxytryptamine receptor 1A	Homo sapiens	129-144	
12923612-5	2003	The selective antagonists p-MPPI and WAY100,635 abolished stimulation of binding by (+)8-OH-DPAT, clozapine and S16924 (p-MPPI), indicating that these actions were mediated specifically by 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	84-96	5-hydroxytryptamine receptor 1A	Homo sapiens	189-196	
14656287-9	2003	8-OH-DPAT, a 5-HT1A receptor agonist, also inhibited Ca(2+) currents in dissociated neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28	
14614949-0	2003	Contribution of the serotonin 5-HT1A receptor agonism of 8-OH-DPAT and EMD 128130 to the regulation of haloperidol-induced muscle rigidity in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Homo sapiens	30-36	
14556235-5	2003	In CHO-K1 cells expressing 5-HT1A receptors, 5-HT and DA inhibited the specific binding of selective antagonist [3H]-8-OH-DPAT with IC50 values of 10.2 nM and 1.4 microM, and both 5-HT and DA inhibited the forskolin-induced accumulation of cAMP.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Homo sapiens	27-33	
12763095-3	2003	Using conventional whole-cell patch recording, we confirmed that the 5-HT(1A) agonist, 8-hydroxy-2-dipropylaminotetralin, presynaptically decreased electrically evoked GABA release while the 5-HT(3) agonist, m-chlorophenylbiguanide (mCPBG), presynaptically facilitated release.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-120	5-hydroxytryptamine receptor 1A	Homo sapiens	69-76	
12787852-2	2003	In view of a role of 5-hydroxytryptamine (5-HT; serotonin)-1A receptors in the elicitation of EPS, the present study concerns pre- and postsynaptic responses to a selective 5-HT-1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) following acute and chronic administration of haloperidol in rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	199-238	5-hydroxytryptamine receptor 1A	Homo sapiens	173-189	
12885442-6	2003	Microinjections of the 5-HT(1A) receptor agonist 8-OHDPAT (0.1, 1.0 and 3.0 nmol) into the medial hypothalamus suppressed PAG-elicited hissing in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-57	5-hydroxytryptamine receptor 1A	Homo sapiens	23-40	
12885442-7	2003	Administration of the 5-HT(1A) antagonist p-MPPI (3.0 nmol) blocked the suppressive effects of 8-OHDPAT upon hissing.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-103	5-hydroxytryptamine receptor 1A	Homo sapiens	22-29	
12892833-7	2003	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-67	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
12892833-7	2003	The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) impaired this response, suggesting an anxiolytic effect, and the preferential 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) was ineffective.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
12818723-4	2003	Thus, after stimulation with forskolin, the agonists dopamine (at D(2A) and D(3)), noradrenaline (at alpha(2C)), or 8-OH-DPAT (at 5-HT(1A)) induced a reduction in cAMP accumulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	130-137	
12684269-4	2003	Ligand binding studies were used to determine dissociation constants for agonist binding to the 5-HT(1A) receptor: (a) K(i) values for agonists were determined in competition versus the binding of the agonist [(3)H]-8-OH DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	216-225	5-hydroxytryptamine receptor 1A	Homo sapiens	96-113	
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-60	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11	
12676358-1	2003	The 5-HT(1A) agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) causes inhibition of caspase-3 and apoptosis via the extracellular signal-regulated kinases (ERK1/2) in hippocampal HN2-5 cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11	
12676358-2	2003	Two 5-HT(1A) agonists, Repinotan hydrochloride (BAY x 3702) and 8-OH-DPAT, block caspase-3 activation and apoptosis caused by anoxia/reoxygenation and H(2)O(2) treatment.	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11	
12676358-7	2003	Finally, transient expression of kinase-negative PKCalpha eliminated the 8-OH-DPAT-evoked block on the H(2)O(2)-triggered caspase-3 stimulation, establishing PKCalpha as a link between ERK and caspase-3 (5-HT(1A)-R-->PLC-->ERK1/2-->PKCalpha-->caspase-3).	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	204-211	
12649391-7	2003	All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	111-128	
12649391-7	2003	All thermic responses to 8-OH-DPAT, including the lethality, were effectively blocked by pretreatment with the 5-HT(1A) receptor antagonist WAY100635, suggesting line differences in thermoregulatory circuits that are influenced by 5-HT(1A) receptor activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	231-248	
12626670-2	2003	In current-clamp mode, activation of 5-HT1A receptors by 8-OH-DPAT led to depolarization and an increase in input resistance in most motoneurons but caused hyperpolarization and a decrease in input resistance in the remaining smaller fraction of cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43	
12588512-4	2003	The 5-HT(1A) agonist 8-OH-DPAT, which had no effect on vasopressin secretion, stimulated oxytocin secretion.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-30	5-hydroxytryptamine receptor 1A	Homo sapiens	4-11	
12237254-6	2002	5 The proportion of 5-HT(1A) receptor binding sites detected by [(3)H]-MPPF that displayed high affinity for 8-OH-DPAT was significantly greater when the interacting G protein contained isoleucine rather than glycine at residue(351).	8-Hydroxy-2-(di-n-propylamino)tetralin	109-118	5-hydroxytryptamine receptor 1A	Homo sapiens	20-37	
12237254-8	2002	7 These results indicate that a higher avidity ternary complex is formed between 8-OH-DPAT, the 5-HT(1A) receptor and G proteins when isoleucine rather than glycine is located at residue(351) of the interacting G protein.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	96-113	
11897085-4	2002	5-HT1A binding sites, as labeled with [3H]8-hydroxy-dipropylaminotetralin (8-OH-DPAT), were highest in the superficial, retinorecipient layers of the tectum, intermediate in layers 6 and 7 and low in the remaining layers.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6	
12004193-3	2002	In addition, the finding that 8-OH-DPAT, CGS-12066A and SC53116 also inhibited AVP-induced flank marking suggests that 5-HT could also inhibit flank marking by acting through 5-HT1A, 5-HT7, 5-HT1B and/or 5-HT4 receptor subtypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	175-181	
12166089-4	2002	The 5-HT and other 5-HT1A receptor agonists, flesinoxan and 8-hydroxy-2- (di-n-propylamino)tetralon (8-OH-DPAT), significantly decreased the population excitatory postsynaptic potential (EPSP) in the CA3-CA1 excitatory synapse in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34	
12031873-6	2002	However, addition of the specific 5-HT(1A) receptor agonist 8-OH-DPAT as well as the alpha1-adrenoceptor antagonist prazosin could not substantially block this tracer accumulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-69	5-hydroxytryptamine receptor 1A	Homo sapiens	34-51	
11275281-0	2001	Role of 5-HT(1A) and 5-HT(7) receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	8-15	
11606626-2	2001	In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-129	5-hydroxytryptamine receptor 1A	Homo sapiens	69-76	
11606626-2	2001	In nucleus raphe dorsalis (NRD) and hippocampus (CA3), the selective 5-HT(1A) agonist (+)-8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT) reduces the firing activity of serotoninergic (5-HT) and pyramidal neurons, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-140	5-hydroxytryptamine receptor 1A	Homo sapiens	69-76	
11595206-0	2001	Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	81-87	
11595206-3	2001	Diazepam (0.1 mg/kg) and the 5-HT(1A) receptor agonist 8-OH-DPAT (0.003 and 0.01 mg/kg) also increased social interaction, whereas an acute dose of the selective serotonin re-uptake inhibitor fluoxetine (10 mg/kg) decreased the time spent in social interaction.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Homo sapiens	29-46	
11448518-7	2001	8-Hydroxy-di-n-propylamino tetralin (8-OH-DPAT), a selective 5-HT(1A) agonist, mimicked the facilitation of 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Homo sapiens	61-68	
11889759-3	2002	Based on our previous experimental studies that 8-OH-DPAT, a potent 5-HT1A agonist, attenuates an increase in L-DOPA-induced extracellular DA in the striatum of the rat model of Parkinson"s disease, we hypothesized that L-DOPA-induced dyskinesia in patients with Parkinson"s disease is alleviated by a 5-HT1A agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	302-308	
11746722-6	2001	When the 5-HT(1A) receptor agonist 8-OH-DPAT was administered intravenously at a dose of 0.1, 0.3, or 1 mg/kg 30 min after tracer injection, binding of [carbonyl-(11)C]WAY-100635 was displaced in both age groups in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	9-26	
11746722-9	2001	In addition, these observations suggested that the age-related impairment of 5-HT(1A) receptor responses to 8-OH-DPAT might be related to the reduced efficacy of antidepressant therapy in elderly patients with depression.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Homo sapiens	77-94	
11569620-0	2001	Effects of histidine on working memory deficits induced by the 5-HT1A-receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-96	5-hydroxytryptamine receptor 1A	Homo sapiens	63-78	
11569620-1	2001	We investigated the effects of histidine on spatial memory deficits induced by the 5-HT1A-receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	108-146	5-hydroxytryptamine receptor 1A	Homo sapiens	83-98	
11275281-9	2001	The present results suggest that the enhancing effect produced by 8-OH-DPAT on learning consolidation involves activation of 5-HT(1A) receptors and an additional mechanism, probably related to the 5-HT(7) receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Homo sapiens	125-132	
11135008-2	2001	We found that 8-hydroxy-2-(n-dipropylamino)tetralin hydrobromide (8-OH-DPAT), a selective 5-HT1A receptor agonist, induced a dose-dependent increase in wakefulness (W) and decrease in deep slow-wave sleep (SWS), but had no significant effect on the generation of paradoxical sleep (PS) at concentrations of 5-500 microM.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-75	5-hydroxytryptamine receptor 1A	Homo sapiens	90-105	
11164517-6	2001	The administration of the selective 5-HT1A agonist, 8-OH-DPAT, counteracted the CTAs produced by MB and 7-NI.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42	
11330332-4	2001	Both 8-OH-DPAT (1 microM) and 5-HT (10 microM) elicited a pronounced increase in [35S]GTPyS binding in the dorsal raphe nucleus, which contains serotonergic cell bodies bearing 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	5-14	5-hydroxytryptamine receptor 1A	Homo sapiens	177-183	
11330332-6	2001	In the dentate gyrus, lateral septum and entorhinal cortex, structures enriched in postsynaptic 5-HT1A receptors, 8-OH-DPAT (1 microM) and 5-HT (10 microM) also elicited a marked increase in [35S]GTPgammaS binding which was likewise blocked by pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-123	5-hydroxytryptamine receptor 1A	Homo sapiens	96-102	
10936212-2	2000	Serotonin, (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT], and buspirone inhibited cyclic AMP production in cells expressing native and mutant 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-48	5-hydroxytryptamine receptor 1A	Homo sapiens	150-157	
11287817-6	2001	), a 5-HT reuptake inhibitor, and 8-hydroxy-2-(di-n-propylamino)tetralin, a 5-HT(1A) receptor agonist, also suppressed the HTR induced by BZ-RAs.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-72	5-hydroxytryptamine receptor 1A	Homo sapiens	76-93	
11069935-7	2000	Both nifedipine, an L-type Ca(2+) channel antagonist, and omega-conotoxin GVIA, a selective N-type channel blocker, abolished the induction of associative LTD. 8-hydroxy-2-dipropylaminotetralin (OH-DPAT), a 5-HT(1A) receptor agonist, inhibited postsynaptic Ca(2+) influx through N-type Ca(2+) channels, without affecting presynaptic transmitter release.	8-Hydroxy-2-(di-n-propylamino)tetralin	160-193	5-hydroxytryptamine receptor 1A	Homo sapiens	207-224	
10991934-2	2000	We studied the effects of low doses of 8-OH-DPAT, a 5-HT(1A) receptor agonist, on the impairment of spatial learning caused by scopolamine injected into the CA1 region of the dorsal hippocampus of rats performing a two-platform spatial discrimination task.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Homo sapiens	52-69	
11077069-8	2001	Both the degree of 5-HT(1A) receptor activation by 8-OH-DPAT and (-)-pindolol, and its inhibition by spiperone, strongly correlate (r(2): 0.78-0.81) with the octanol/water partition coefficients of the mutated amino acid at position 351 of the G(alphai3) protein.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	19-36	
11198126-6	2000	Administration of the 5-HT1A antagonists WAY-100635 and NAN-190 alone produced dose-dependent rate-decreasing effects, but the effects on accuracy of responding in the acquisition components differed from those of the 5-HT1A agonists (8-OH-DPAT and LY228729), in that they did not produce an increase in the percentage of errors.	8-Hydroxy-2-(di-n-propylamino)tetralin	235-244	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28	
10936212-2	2000	Serotonin, (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT], and buspirone inhibited cyclic AMP production in cells expressing native and mutant 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-63	5-hydroxytryptamine receptor 1A	Homo sapiens	150-157	
10884564-3	2000	Microiontophoretic ejection of either the selective serotonin(1A) (5-HT(1A)) agonist (+)8-OH-DPAT or the 5-HT(1B/1D) agonist alniditan resulted in the reversible suppression of the response to superior sagittal sinus stimulation of 29/46 and 18/20 trigeminal neurones, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	67-74	
10952674-6	2000	Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-69	5-hydroxytryptamine receptor 1A	Homo sapiens	174-191	
10952674-6	2000	Finally, the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; 1 microM) inhibited the NMDA-evoked cyclic GMP response, an effect blocked by the selective 5-HT(1A) receptor antagonist WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	71-80	5-hydroxytryptamine receptor 1A	Homo sapiens	174-191	
10900249-5	2000	and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT(1A) agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	173-182	5-hydroxytryptamine receptor 1A	Homo sapiens	156-163	
10900249-5	2000	and s.c. administration, LY426965 blocked the lower lip retraction, flat body posture, hypothermia, and increase in rat serum corticosterone induced by the 5-HT(1A) agonist 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin).	8-Hydroxy-2-(di-n-propylamino)tetralin	184-217	5-hydroxytryptamine receptor 1A	Homo sapiens	156-163	
10884564-5	2000	Microiontophoretic ejection of the selective 5-HT(1A) receptor antagonist WAY-100635 significantly antagonised the effect of (+)8-OH-DPAT (effect reduced by 30%, P<0.05).	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	45-62	
10882396-5	2000	Saturation studies using [(3)H]-8-OH-DPAT and [(3)H]-MPPF revealed a single, high affinity site (K(D)approximately 1 nM) in HEK293 cells expressing human 5-HT(1A) receptors and rat cortex.	8-Hydroxy-2-(di-n-propylamino)tetralin	32-41	5-hydroxytryptamine receptor 1A	Homo sapiens	154-161	
10676857-1	2000	The stereoselectivity of the serotonin1A (5-HT1A) receptor compound 8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) on forskolin-stimulated adenylyl cyclase activity was investigated in membranes from human 5-HT pre-synaptic (raphe nuclei) and post-synaptic (hippocampus and prefrontal cortex) regions of autopsy brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-105	5-hydroxytryptamine receptor 1A	Homo sapiens	29-58	
10899359-0	2000	MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-102	5-hydroxytryptamine receptor 1A	Homo sapiens	36-43	
10823340-6	2000	Systemic administration of the selective 5-HT1A receptor agonist 8-OHDPAT induces dose-dependent effects; i.e. low doses increase slow wave sleep and reduce waking, whereas large doses increase waking and reduce slow wave sleep and REM sleep.	8-Hydroxy-2-(di-n-propylamino)tetralin	65-73	5-hydroxytryptamine receptor 1A	Homo sapiens	41-56	
10676857-1	2000	The stereoselectivity of the serotonin1A (5-HT1A) receptor compound 8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) on forskolin-stimulated adenylyl cyclase activity was investigated in membranes from human 5-HT pre-synaptic (raphe nuclei) and post-synaptic (hippocampus and prefrontal cortex) regions of autopsy brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	29-58	
10515324-4	1999	Tests for generalization and antagonism showed that 5-HT1A receptor agonists, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) (66.7%), flesinoxan (72.7%), buspirone (58.3%), and ipsapirone (36.4%) only partially substituted for the eltoprazine cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	52-67	
10541727-7	1999	The prototypical 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-(2-di-n-propylamino)tetralin] substituted for LY233708.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	17-24	
10541727-7	1999	The prototypical 5-HT(1A) agonist, 8-OH-DPAT [8-hydroxy-(2-di-n-propylamino)tetralin] substituted for LY233708.	8-Hydroxy-2-(di-n-propylamino)tetralin	46-84	5-hydroxytryptamine receptor 1A	Homo sapiens	17-24	
10412836-0	1999	Modulation of sympathetic nerve activity by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the rostroventrolateral medulla.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Homo sapiens	66-81	
10412836-6	1999	This study demonstrates that differential inhibition of regional sympathetic outflows can be elicited by microinjection of the 5-HT1A receptor agonist 8-OH-DPAT into the RVLM.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Homo sapiens	127-142	
9878719-4	1999	5-HT and the 5-HT1A receptor agonist, (+)8-hydroxy-2(di-N-propylamino)tetraline (8-OH-DPAT), were able to inhibit forskolin-stimulated adenylyl cyclase activity in a dose-dependent manner for 48 h after death in rat and human brain.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28	
10379620-4	1999	RESULTS: Firstly, the 5-HT1A agonists 8-OH-DPAT and ipsapirone attenuated the extrapyramidal-like effects of haloperidol and risperidone more than their therapeutic-like effects; this was not observed for tropapride, where all of its effects were markedly attenuated.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28	
10379620-6	1999	Thirdly, neuroleptics apparently differed in their sensitivity to interactions with 5-HT1A agonists inasmuch as 8-OH-DPAT and ipsapirone attenuated the effects of tropapride on hindlimb retraction times more than those of haloperidol or risperidone.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Homo sapiens	84-90	
10188639-5	1999	Similarly, quantitative autoradiography using the radiolabeled 5-HT(1A) receptor agonist 8-hydroxy-2-(di-N-propylamino) tetralin demonstrated a significant decline in receptor density in 3- and 13-month MC and HC groups as compared to age-matched LC groups in the hippocampus.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-128	5-hydroxytryptamine receptor 1A	Homo sapiens	63-80	
10100214-9	1999	[11C]NAD-299 binding was inhibited by addition of the 5-HT1A receptor ligands WAY-100635, pindolol, (+/-)-8-OH-DPAT, 5-HT, and buspirone, leaving a low background of nonspecific binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-115	5-hydroxytryptamine receptor 1A	Homo sapiens	54-69	
9878719-11	1999	The (+)8-OH-DPAT dose-response curve was completely reversed by 5-HT1A receptor antagonists in rat cortex and all human brain areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	7-16	5-hydroxytryptamine receptor 1A	Homo sapiens	64-79	
9826061-0	1998	Dimerization of 8-OH-DPAT increases activity at serotonin 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	16-25	5-hydroxytryptamine receptor 1A	Homo sapiens	58-64	
9817696-2	1998	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A and 5-HT7 agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Homo sapiens	56-62	
9817696-2	1998	8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) is a 5-HT1A and 5-HT7 agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	56-62	
9845002-4	1998	The main response to serotonin application (2-20 microM) was an inhibition that could be mimicked by 8-OH-DPAT (a 5-HT1A receptor agonist).	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Homo sapiens	114-129	
9836617-1	1998	A series of four racemic ring-substituted trans-2-(indol-3-yl)cyclopropylamine derivatives was synthesized and tested for affinity at the 5-HT1A receptor, by competition with [3H]-8-OH-DPAT in rat hippocampal homogenates, and for affinity at the agonist-labeled cloned human 5-HT2A, 5-HT2B, and 5-HT2C receptor subtypes.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine receptor 1A	Homo sapiens	138-153	
9826061-6	1998	Hence, the 8-OH-DPAT dimer shows increased efficacy at 5-HT1A receptors compared to 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-20	5-hydroxytryptamine receptor 1A	Homo sapiens	55-61	
12580024-13	1998	The selective 5-HT1A agonist (+)-8-OH-DPAT (10(-8)-10(-5) M) had no significant effect, but at concentration of 10(-4) M, inhibited evoked 3H-Ach.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-42	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20	
9744926-7	1998	Although the serotonin agonists for the 5-HT1B,2C,3 receptors were ineffective, the effects were mimicked by the 5-HT1A-receptor agonists (8-OH-DPAT, 5-CT) and prevented by the 5-HT1A-receptor antagonist NAN-190.	8-Hydroxy-2-(di-n-propylamino)tetralin	139-148	5-hydroxytryptamine receptor 1A	Homo sapiens	113-128	
9721928-3	1998	We constructed cumulative concentration response curves to the selective 5-HT1A agonist (+)-8-OH-DPAT on both extracellular recordings of 5-HT neurones and electrically stimulated 5-HT release in dorsal raphe brain slices.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-101	5-hydroxytryptamine receptor 1A	Homo sapiens	73-79	
9721928-4	1998	Chronic paroxetine desensitized the 5-HT1A receptors controlling firing, with an increase in EC50 from 10.7 nM to 46.2 nM 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Homo sapiens	36-42	
9920534-5	1998	The selective 5-HT1A receptor antagonist WAY100635 produced a potent (IC50, 2.3 nM) and complete block of the 8-OH-DPAT-stimulated response.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Homo sapiens	14-29	
9651229-5	1998	Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-174	5-hydroxytryptamine receptor 1A	Homo sapiens	120-126	
9651229-5	1998	Discharge activity of REM-on neurons was almost completely suppressed by local microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), although this agonist had minimal or no effect on the Wake/REM-on neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Homo sapiens	120-126	
9884126-6	1998	They demonstrated: (1) that the androgenic and estrogenic metabolites of testosterone differentially modulate the ability of systemically administered 8-OH-DPAT (a 5HT1A agonist) and CGS12066B (a 5HT1B agonist) to decrease offensive aggression; and (2) when microinjected into the lateral septum (LS) or medial preoptic area (MPO), the aggression-attenuating effects of 1A and 1B agonists differ regionally and vary with the steroidal milieu.	8-Hydroxy-2-(di-n-propylamino)tetralin	151-160	5-hydroxytryptamine receptor 1A	Homo sapiens	164-169	
9871775-4	1998	Surprisingly enough, the dimer of 8-OH-DPAT 6 binds to 5HT1A, 5HT1B and 5HT1D receptors with similar high affinity.	8-Hydroxy-2-(di-n-propylamino)tetralin	34-43	5-hydroxytryptamine receptor 1A	Homo sapiens	55-60	
9536454-3	1998	The data indicate that the reversal of haloperidol-induced EPS by (+/-)-8-OH-DPAT and its enantiomers is mediated via effects at 5-HT1A receptors, not dopamine D2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-81	5-hydroxytryptamine receptor 1A	Homo sapiens	129-135	
9553162-18	1998	Receptor-specific binding was eliminated in the presence of the selective 5-HT1A receptor agonist, 8-OH-DPAT [(+/-)-8-hydroxy-2-dipropylaminotetralin].	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	74-89	
9553162-18	1998	Receptor-specific binding was eliminated in the presence of the selective 5-HT1A receptor agonist, 8-OH-DPAT [(+/-)-8-hydroxy-2-dipropylaminotetralin].	8-Hydroxy-2-(di-n-propylamino)tetralin	110-149	5-hydroxytryptamine receptor 1A	Homo sapiens	74-89	
9435153-5	1998	In contrast to sigma ligands and other reference compounds, the 5-HT1A agonists buspirone, 8-OH-DPAT and spiroxatrine dose-dependently produced BMY 14802-like discriminative stimulus effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-100	5-hydroxytryptamine receptor 1A	Homo sapiens	64-70	
9427327-2	1997	8-OH-DPAT increased the hybridization signal of the 5-HT1A receptor by 105% in the dorsal raphe nucleus (B7) 30 min after the injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	52-67	
9427327-5	1997	At 8 h following 8-OH-DPAT injection, the effect had shifted to an increase in 5-HT1A receptor labeling by 68% in the B8 area.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Homo sapiens	79-94	
9347319-2	1997	The binding characteristics of tritium labeled 8-hydroxy-dipropyl-aminotetralin, or [3H]8-OH-DPAT, to the serotonin1A (5-HT1A) receptor in the stably transfected HeLa cell clone HA6 and in human cortical tissue were examined and compared.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	106-135	
9369342-8	1997	Bromerguride decreased neither forskolin-stimulated cAMP accumulation nor extracellular 5-HT; instead, it antagonized the decrease of cAMP accumulation produced by 5-HT and the decrease of extracellular 5-HT produced by the 5-HT1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	239-283	5-hydroxytryptamine receptor 1A	Homo sapiens	224-230	
9369342-8	1997	Bromerguride decreased neither forskolin-stimulated cAMP accumulation nor extracellular 5-HT; instead, it antagonized the decrease of cAMP accumulation produced by 5-HT and the decrease of extracellular 5-HT produced by the 5-HT1A agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	285-294	5-hydroxytryptamine receptor 1A	Homo sapiens	224-230	
9105876-3	1997	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced temperature reduction, lower lip retraction and tail flick responses are widely used models of 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-38	5-hydroxytryptamine receptor 1A	Homo sapiens	154-169	
9316875-3	1997	Paroxetine reduced the oxytocin, adrenal corticotropic hormone and corticosterone responses to a challenge with the 5-HT1A agonist 8-hydroxy-2-(dipropylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-166	5-hydroxytryptamine receptor 1A	Homo sapiens	116-122	
9314029-1	1997	Using in vivo extracellular recordings, we have examined the effect of the application of the prototypical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), on the firing rate of locus coeruleus neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-170	5-hydroxytryptamine receptor 1A	Homo sapiens	107-122	
9314029-1	1997	Using in vivo extracellular recordings, we have examined the effect of the application of the prototypical 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), on the firing rate of locus coeruleus neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	172-181	5-hydroxytryptamine receptor 1A	Homo sapiens	107-122	
9313892-7	1997	Administration of the selective 5-HT1A antagonist, 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl] ethyl]-N-2-pyridinyl-benzamide hydrochloride (p-MPPI) (1.5 and 3.0 nmol), blocked the suppressive effects of 8-OHDPAT upon hissing.	8-Hydroxy-2-(di-n-propylamino)tetralin	206-214	5-hydroxytryptamine receptor 1A	Homo sapiens	32-38	
9272757-0	1997	On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	61-68	
9272757-0	1997	On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	79-88	5-hydroxytryptamine receptor 1A	Homo sapiens	189-195	
9272757-9	1997	These data suggest that the anxiolytic-like effects of 8-OH-DPAT, but not the anxiogenic-like effects of buspirone, on the elevated plus-maze are mediated via 5-HT(1A) receptors in the CNS.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Homo sapiens	159-166	
9152998-7	1997	Using [3H]WAY-100635, we confirmed an increase of 5-HT1A receptor binding sites in the frontal cortex in schizophrenia, previously demonstrated with [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	153-162	5-hydroxytryptamine receptor 1A	Homo sapiens	50-65	
9152998-10	1997	First, they indicate that the elevated [3H]8-OH-DPAT binding seen in the same cases is attributable to an increase of 5-HT1A receptors rather than any other binding site.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	118-124	
9152998-11	1997	Second, the enhanced [3H]8-OH-DPAT binding in schizophrenia reflects an increased density of 5-HT1A receptors, not an increased percentage of 5-HT1A receptors which are G-protein-coupled.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99	
9203529-1	1997	The effects of gender, aging and gender x age on the binding of the 5-HT1A receptor high-affinity agonist [3H]8-hydroxy-2(di-N-propylamino)tetralin ([3H]8-OH-DPAT), were evaluated and compared in tissues of human prefrontal, temporal, parietal, occipital cortex and hippocampus obtained from 21 autopsy subjects.	8-Hydroxy-2-(di-n-propylamino)tetralin	149-162	5-hydroxytryptamine receptor 1A	Homo sapiens	68-83	
9164586-2	1997	Pretreatment with p-MPPI reduced or blocked the effect of the 5-HT1A receptor agonist 8-OH-DPAT on two responses mediated by postsynaptic 5-HT1A receptors, reduction of body temperature and the 5-HT behavioral syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77	
9164586-2	1997	Pretreatment with p-MPPI reduced or blocked the effect of the 5-HT1A receptor agonist 8-OH-DPAT on two responses mediated by postsynaptic 5-HT1A receptors, reduction of body temperature and the 5-HT behavioral syndrome.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	62-68	
9164586-4	1997	Pretreatment with p-MPPI also blocked the ability of 8-OH-DPAT to reduce extracellular 5-HT in the striatum, a response mediated by presynaptic 5-HT1A receptors in the dorsal raphe nucleus, but did not alter striatal 5-HT when administered alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-62	5-hydroxytryptamine receptor 1A	Homo sapiens	144-150	
9218690-1	1997	The present study was undertaken to compare the properties of the [3H]8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) binding site in the dorsal raphe nucleus with the hippocampal 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	66-79	5-hydroxytryptamine receptor 1A	Homo sapiens	183-198	
9218690-3	1997	[3H]8-OH-DPAT appears to bind to a single population of binding sites in both the hippocampus and the dorsal raphe nucleus, although the K(d) for the radioligand at the dorsal raphe site was five times that observed at the hippocampal 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	4-13	5-hydroxytryptamine receptor 1A	Homo sapiens	235-250	
9218690-4	1997	Similarly, although 5-HT and selective 5-HT1A receptor ligands displayed high affinity for the [3H]8-OH-DPAT binding site in the dorsal raphe nucleus, the affinity at the dorsal raphe site was less than that observed at the hippocampal 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	39-54	
9218690-8	1997	However, addition of another putative 5HT1A receptor selective ligand, buspirone, did not alter the generation of [3H]inositol phosphates, but blocked the inhibitory effect of 8-OH-DPAT on phosphoinositide hydrolysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	176-185	5-hydroxytryptamine receptor 1A	Homo sapiens	38-52	
9218690-9	1997	These studies demonstrate that the 8-OH-DPAT binding site in the dorsal raphe nucleus displays a binding profile which is similar to the hippocampal 5-HT1A receptor, but unlike this 5-HT1A receptor the binding site in the dorsal raphe nucleus is negatively coupled to phosphoinositide turnover.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	149-164	
9218690-9	1997	These studies demonstrate that the 8-OH-DPAT binding site in the dorsal raphe nucleus displays a binding profile which is similar to the hippocampal 5-HT1A receptor, but unlike this 5-HT1A receptor the binding site in the dorsal raphe nucleus is negatively coupled to phosphoinositide turnover.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	182-197	
9163561-3	1997	Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106	
9163561-3	1997	Tests for generalization and antagonism showed that compounds with agonistic action at the 5-HT1A receptor, such as 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin), buspirone and ipsapirone all substituted for the flesinoxan cue.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-165	5-hydroxytryptamine receptor 1A	Homo sapiens	91-106	
9105876-3	1997	8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)-induced temperature reduction, lower lip retraction and tail flick responses are widely used models of 5-HT1A receptor function.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-49	5-hydroxytryptamine receptor 1A	Homo sapiens	154-169	
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77	
9067310-19	1997	Finally, VTA neurones are stimulated by (+)-8-OH-DPAT via 5-HT1A receptors and inhibited by (-)-8-OH-DPAT via hD3 and/or hD2 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	40-53	5-hydroxytryptamine receptor 1A	Homo sapiens	58-64	
9067310-4	1997	In binding studies, racemic 8-OH-DPAT showed 100-fold selectivity for h5-HT1A vs. hD2 and hD3 receptors and there was little difference between its (+)- and (-)-isomers either in terms of their potency at 5-HT1A receptors or of their selectivity at 5-HT1A vs hD2/hD3 sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Homo sapiens	205-211	
9105961-1	1997	5-HT1A receptor binding sites were measured, by saturation binding with [3H]8-OH-DPAT, in frontal and occipital cortex, hippocampus and amygdala obtained at post-mortem examination from suicide victims with a firm retrospective diagnosis of depression, and matched controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15	
9016944-3	1996	Dose-effect curves obtained by simultaneously applying equipotent concentrations of the selective 5-HT1A agonist 8-OH-DPAT and the selective 5-HT1D receptor agonist sumatriptan are shifted to the right, although maximal effects are additive.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Homo sapiens	98-104	
9017662-4	1997	The pharmacological profile of the [3H]8-OH-DPAT binding sites was consistent with the labelling of the 5-HT1A receptor in the hippocampus and cortex, whereas the striatal site shared strong similarity to the presynaptic serotonin transporter.	8-Hydroxy-2-(di-n-propylamino)tetralin	39-48	5-hydroxytryptamine receptor 1A	Homo sapiens	104-119	
9421130-11	1997	In 24FD pigeons, the 5-HT1a agonist 8-OH-DPAT (30.5 nmol) induced strong dipsogenic effects, as well as increase in food intake duration.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-45	5-hydroxytryptamine receptor 1A	Homo sapiens	21-27	
9037397-5	1997	The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Homo sapiens	22-28	
9037397-5	1997	The labeling of human 5-HT1A receptors with [3H]WAY-100635 was antagonised by the addition of 5-HT1A receptor ligands, 5-HT, buspirone, pindolol or 8-OH-DPAT (10 microM), leaving a very low background of non-specific binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	148-157	5-hydroxytryptamine receptor 1A	Homo sapiens	22-37	
9048968-1	1997	The ligand binding characteristics of the recombinant human 5-HT1A receptor stably expressed in a Chinese Hamster Ovary (CHO) cell line are described using a selective agonist, [3H]8-OH-DPAT, and a novel antagonist radioligand, [3H]WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	181-190	5-hydroxytryptamine receptor 1A	Homo sapiens	60-75	
9048968-7	1997	Furthermore, [3H] 8-OH-DPAT labelled approximately 53-61% of total 5-HT1A sites recognised by [3H]WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	67-73	
9048968-8	1997	The competition binding profiles of [3H]WAY-100635 and [3H]8-OH-DPAT were highly correlated and consistent with the recognition of 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	131-137	
9048968-10	1997	A significant correlation between the respective affinities of a range of agonists and antagonists at recombinant human and rodent hippocampal 5-HT1A binding sites (previously published) was also observed using [3H]WAY-100635 (r = 0.92; P < 0.0005) and [3H]8-OH-DPAT (r = 0.96; P < 0.0005).	8-Hydroxy-2-(di-n-propylamino)tetralin	260-269	5-hydroxytryptamine receptor 1A	Homo sapiens	143-149	
11224433-6	1996	We also found that three doses of the 5-HT(1A) agonist, 8-OH-DPAT, caused a biphasic dose effect on impulsivity.	8-Hydroxy-2-(di-n-propylamino)tetralin	56-65	5-hydroxytryptamine receptor 1A	Homo sapiens	38-45	
9085496-5	1996	Both CGS-12066 and 8-OH-DPAT (5HT1B and 5HT1A receptor agonists, respectively) suppressed XII nerve activity in a dose-dependent manner by about 20%.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	40-54	
8923668-5	1996	The specific binding of the radioligand in the hippocampal region, an area rich in 5-HT1A receptor density, was blocked by a chasing dose of (+/-) 8-OH-DPAT (2 mg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	147-156	5-hydroxytryptamine receptor 1A	Homo sapiens	83-98	
8819496-7	1996	Pretreatment of P11-5HT1A cells with the phorbol ester, phorbol 12-myristate 13-acetate (PMA), also resulted in desensitization of the 5-HT1A receptor, as indicated by a marked decrease in the potency and intrinsic activity of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	227-236	5-hydroxytryptamine receptor 1A	Homo sapiens	135-150	
8798386-3	1996	Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate.	8-Hydroxy-2-(di-n-propylamino)tetralin	60-111	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41	
8798386-3	1996	Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate.	8-Hydroxy-2-(di-n-propylamino)tetralin	113-122	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41	
8865198-4	1996	The current (dose)-dependent inhibition produced by the serotonin agonists did not differ significantly from the inhibition produced by MDMA except for the 5-HT1A agonist 8-hydroxy-(2-di-n-propylamino) tetralin, which inhibited glutamate-evoked firing significantly more than MDMA or any of the other serotonin agonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-210	5-hydroxytryptamine receptor 1A	Homo sapiens	156-162	
9162203-0	1996	Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia.	8-Hydroxy-2-(di-n-propylamino)tetralin	25-34	5-hydroxytryptamine receptor 1A	Homo sapiens	56-63	
8841890-2	1996	A high density of 5-HT1A receptors, labeled by [3H]8-hydroxy-2-(di-n-propylamino)tetralin ([3H]8-OH-DPAT), was found in the superficial layers of the dorsal horn, with a significant enrichment ( approximately 20%) in the lumbar vs. the thoracic and cervical segments.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-104	5-hydroxytryptamine receptor 1A	Homo sapiens	18-24	
9162203-2	1996	In view of the evidence that one serotonin (5-HT) receptor, the 5-HT(1A) subtype, is associated with cortical glutamatergic neurons, we have used quantitative receptor autoradiography to measure the specific binding of the 5-HT(1A) receptor ligand [3H]8-OH-DPAT (2 nM) in sections of orbital frontal cortex taken from 18 control and 12 schizophrenic postmortem brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	252-261	5-hydroxytryptamine receptor 1A	Homo sapiens	64-71	
9162203-2	1996	In view of the evidence that one serotonin (5-HT) receptor, the 5-HT(1A) subtype, is associated with cortical glutamatergic neurons, we have used quantitative receptor autoradiography to measure the specific binding of the 5-HT(1A) receptor ligand [3H]8-OH-DPAT (2 nM) in sections of orbital frontal cortex taken from 18 control and 12 schizophrenic postmortem brains.	8-Hydroxy-2-(di-n-propylamino)tetralin	252-261	5-hydroxytryptamine receptor 1A	Homo sapiens	223-240	
8632301-3	1996	The 5-HT1A agonists, buspirone and 8-OH-DPAT, which lack affinity for 5-HT2A/2C receptors, produced dose-related increases in punished responding.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-44	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
8882616-7	1996	The 5-HT1A receptor agonist, (+/-)-8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT) (10 to 3000 nM) induced a concentration-dependent increase (P < 0.05) in Na+, K(+)-ATPase activity with an EC50 value of 355 nM (95% confidence limits: 178, 708).	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
8882616-8	1996	Maximal stimulation elicited by 3000 nM of 8-OH-DPAT was antagonized by the selective 5-HT1A receptor antagonist, (+)-WAY 100135 10 to 1000 nM) with an IC50 value of 20 nM (14, 29); 0.3 microM (+)-WAY 100135 completely abolished (P < 0.01) the stimulatory effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101	
8882616-8	1996	Maximal stimulation elicited by 3000 nM of 8-OH-DPAT was antagonized by the selective 5-HT1A receptor antagonist, (+)-WAY 100135 10 to 1000 nM) with an IC50 value of 20 nM (14, 29); 0.3 microM (+)-WAY 100135 completely abolished (P < 0.01) the stimulatory effect of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	269-278	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101	
8801608-4	1996	With 5-HT agonists, 8-OH-DPAT (5-HT1A) suppressed the two oral stereotypies and increased standing (all 1.0 mg/kg) and preening (0.2 mg/kg), alpha-methylserotonin (5-HT2) suppressed the oral stereotypies and increased sitting (all 1.0 mg/kg), and m-CPBG (5-HT3) suppressed drinker-directed activity (1.0 mg/kg).	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Homo sapiens	31-37	
9005436-5	1996	The simulations indicated that the 5-HT(1a) receptor agonists, (R)- and (S)-8-OH-DPAT and (R)-UH-301, interacted with the receptor at a site closer to Asp82 in TMH2 than did (S)-UH-301, which is a 5-HT1a receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-85	5-hydroxytryptamine receptor 1A	Homo sapiens	35-52	
9005436-1	1996	A three-dimensional model of the human 5-HT(1a) receptor was constructed by molecular modelling, and the molecular and electronic structures of (R)- and (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin (UH-301) and of (R)- and (S)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) were examined by molecular mechanics and quantum mechanics calculations and molecular dynamics simulations.	8-Hydroxy-2-(di-n-propylamino)tetralin	268-277	5-hydroxytryptamine receptor 1A	Homo sapiens	39-56	
9005436-3	1996	Interactions of UH-301 and 8-OH-DPAT with the 5-HT(1a) receptor were examined by molecular dynamics simulations and energy minimization of receptor-ligand complexes.	8-Hydroxy-2-(di-n-propylamino)tetralin	27-36	5-hydroxytryptamine receptor 1A	Homo sapiens	46-63	
9005436-5	1996	The simulations indicated that the 5-HT(1a) receptor agonists, (R)- and (S)-8-OH-DPAT and (R)-UH-301, interacted with the receptor at a site closer to Asp82 in TMH2 than did (S)-UH-301, which is a 5-HT1a receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-85	5-hydroxytryptamine receptor 1A	Homo sapiens	197-212	
7671319-5	1995	Spiperone and NAN-190, antagonists to 5-HT1A receptor subtype, abolished the serotonin effects on calcium signaling, whereas an agonist to 5-HT1A receptor, 8OHDPAT, mimicked the serotonin-like action on the diminution of the intracellular calcium contents.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-163	5-hydroxytryptamine receptor 1A	Homo sapiens	139-154	
8551355-7	1996	After abolishing the crossed IPSPs by spinal transection, systemic administration of the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT; 0.1-1.3 mg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	113-170	5-hydroxytryptamine receptor 1A	Homo sapiens	89-104	
8566173-2	1995	We now report that the 5-HT1A receptor agonist R(+)-8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT) is also capable of stimulating [3H]thymidine incorporation into SCLC GLC-8 cells, although with lower efficacy than 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Homo sapiens	23-38	
8566173-4	1995	The 5-HT1A receptor antagonists spiperone and SDZ 216-525 completely abolished the effect of 8-OH-DPAT (IC50 30 nM for both drugs) behaving as pure antagonists.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
9328612-3	1996	In the second study we have compared the effectiveness of intracerebroventricular and intravenous administration of 8-OH-DPAT in frequently used behavioural models of 5-HT1A receptor activation, namely lower lip retraction, body temperature and tail flick responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	167-182	
9328615-2	1996	WAY 100635 selectively blocked 5-HT1A receptor-mediated responses of 5-HT, 8-OH-DPAT, lesopitron and 5-CT.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Homo sapiens	31-46	
8788510-5	1996	An interesting finding was that blockade [3H]5-CT binding to 5-HT1A receptors by 8-OH-DPAT could only be achieved at very high concentrations of the displacer.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	61-67	
8979820-3	1996	Autoradiography of tissue sections exposed to [3H]-8-OH-DPAT (8-hydroxy-dipropylaminotetraline) or to [125I]cyanopindolol plus isoproterenol showed that 5-HT1A and 5-HT1B receptors, respectively, were present in the superficial SC layers.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	153-159	
8742464-2	1995	In the present study the CCKA receptor antagonist devazepide (50-200 micrograms kg-1, s.c.) was found reliably to potentiate the feeding response elicited by dorsal or median raphe injection of the 5-HT1A agonist 8-OH-DPAT (0.2-0.8 nmol).	8-Hydroxy-2-(di-n-propylamino)tetralin	213-222	5-hydroxytryptamine receptor 1A	Homo sapiens	198-204	
7562940-4	1995	All compounds showed high affinity at 5-HT1A sites (8.10 < or = pKis < or = 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses.	8-Hydroxy-2-(di-n-propylamino)tetralin	195-204	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44	
7540664-5	1995	Preincubation of transfected HeLa cell membranes with Ab-2 antibodies revealed two affinity binding sites of the 5-HT1A receptor (KDH = 0.54 +/- 0.09 nM and KDL = 13.74 +/- 4.9 nM) for the agonist 8-hydroxy-2-(di-n-[3H]propylamino) tetralin ([3H]8-OH-DPAT) binding, but Ab-1 and Ab-12 revealed only one site (KD of approximately 2.5 nM).	8-Hydroxy-2-(di-n-propylamino)tetralin	242-255	5-hydroxytryptamine receptor 1A	Homo sapiens	113-128	
8524978-6	1995	The 5HT1A agonist 8-OH-DPAT produced drug-appropriate responding at higher doses (0.3-1.0 mg/kg), whereas much lower doses (0.003-1.0 mg/kg) antagonized the methamphetamine stimulus.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	4-9	
8539333-2	1995	5-HT1A receptors have been cloned and a variety of selective agonists, such as the aminotetraline 8-OH-DPAT and the pyrimidinylpiperazine ipsapirone, have become available.	8-Hydroxy-2-(di-n-propylamino)tetralin	98-107	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6	
7608342-2	1995	The 5-HT1A receptor has been shown to mediate motoneuron responses in spinal reflex pathways using the highly selective 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-153	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
7662151-2	1995	The 5-HT1A agonist 8-OH-DPAT was microinjected into the region of the DRN either before exposure to IS or before testing for fear conditioning and escape learning conducted 24 hr later.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
7566497-4	1995	The BMY7378- and 8-OH-DPAT-induced inhibition of 5-HT release were reversed by a 40 min pre-treatment with either (+/-)pindolol (8 mg/kg, s.c.) or WAY-100635 (0.3 mg/kg, s.c.), to block 5-HT1A autoreceptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	17-26	5-hydroxytryptamine receptor 1A	Homo sapiens	186-192	
7667330-6	1995	Further, a correlation analysis across each of the above agonists, as well as 8-OH-DPAT, buspirone, and (+)-flesinoxan, revealed a significant correlation for their relative potency in augmenting punished responding and their affinity for 5-HT1A receptors in vitro (r = +0.95, p < 0.001).	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Homo sapiens	239-245	
7608342-2	1995	The 5-HT1A receptor has been shown to mediate motoneuron responses in spinal reflex pathways using the highly selective 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	144-153	5-hydroxytryptamine receptor 1A	Homo sapiens	120-135	
7777653-5	1995	The 5-HT1A agonist, 8-OH-DPAT, was able to attenuate the adrenocortical responses to acoustic stimulation, conditioned fear, IL-1 alpha, and cocaine administration, with ipsapirone also being effective in reducing the responses to acoustic stimulation and cocaine injection.	8-Hydroxy-2-(di-n-propylamino)tetralin	20-29	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
7550544-0	1995	Attenuation of the fentanyl-induced muscle rigidity by the selective 5HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	69-74	
7550544-2	1995	The selective 5HT1A receptor agonist 8-OH-DPAT (0.1, 0.3 and 1.0 mg/kg ip) showed only a tendency to attenuate the natural muscle tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-46	5-hydroxytryptamine receptor 1A	Homo sapiens	14-28	
7824554-3	1994	Both the unconditioned and conditioned emetic responses were dose-dependently blocked by 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT) and LY228729, agonists at the 5-HT1A subtype of serotonin receptor, but not by the 5-HT3, antagonist tropisetron.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Homo sapiens	168-174	
7705452-9	1994	Substantial (77%) blockade of [3H]WAY-100635 binding was achieved with the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), and the partial agonists, ipsapirone and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Homo sapiens	75-81	
7855734-0	1994	5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6	
7886629-6	1994	The specific binding of the radioligand in the hippocampal region, an area rich in 5-HT1A receptor density, was blocked by pretreatment with a dose of (+/-) 8-OH-DPAT (2 mg/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	157-166	5-hydroxytryptamine receptor 1A	Homo sapiens	83-98	
7824554-5	1994	NAN-190, a putative 5-HT1A partial agonist, produced both an antiemetic response when administered before DTG and also attenuated the antiemetic effects of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Homo sapiens	20-26	
7834355-3	1994	The expression study revealed that 5HT1A mRNA distribution in the hippocampus and prefrontal cortex was consistent with the data of the [3H]8-OH-DPAT binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Homo sapiens	35-40	
7993956-7	1994	In conclusion, the present results confirm our previous results using 8-OH-DPAT as a challenge, and suggest that chronic 5-HT uptake inhibition results in adaptive changes leading to decreased function of the 5-HT1A receptor system.	8-Hydroxy-2-(di-n-propylamino)tetralin	70-79	5-hydroxytryptamine receptor 1A	Homo sapiens	209-224	
7820591-4	1994	injection of the 5-HT1A receptor agonist, 8-OH-DPAT, during the dark phase (6 h after lights-off) significantly reduced the extracellular glutamate concentration in the SCN region from baseline levels (38.7 +/- 8.7 and 53.4 +/- 11.2%, respectively, of pretreatment values; P < 0.05).	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Homo sapiens	17-32	
7862933-4	1994	In drug discrimination studies, pigeons were trained to discriminate injections of the 5-HT1A agonist 8-OH-DPAT (0.3 mg/kg) from saline.	8-Hydroxy-2-(di-n-propylamino)tetralin	102-111	5-hydroxytryptamine receptor 1A	Homo sapiens	87-93	
7862933-9	1994	All compounds substituted for 8-OH-DPAT in the drug discrimination procedure, suggestive of 5-HT1A agonist activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
7522172-0	1994	Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Homo sapiens	106-121	
7988650-3	1994	At 25 micrograms/kg, 8-hydroxy-2-(di-n-propylamino)tetralin, an agonist at 5-HT1A receptors, reduced cortical 5-HT output in controls but not in animals treated chronically with citalopram whereas 50 micrograms/kg reduced 5-HT output in both groups.	8-Hydroxy-2-(di-n-propylamino)tetralin	21-59	5-hydroxytryptamine receptor 1A	Homo sapiens	75-81	
8021490-9	1994	Inhibition by metitepine is reversed by 5HT and by the selective 5HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	121-130	5-hydroxytryptamine receptor 1A	Homo sapiens	65-79	
8138923-1	1994	Exposure of HeLa cells stably expressing cloned human 5-hydroxytryptamine (5-HT)1A receptors (HA7 cells) to the agonist 8-hydroxy-2-(di-N-propylamino)-tetralin (8-OH-DPAT) results in a loss of high-affinity binding sites and a desensitization of receptor-adenylate cyclase coupling, as measured by 5-HT1A-mediated inhibition of forskolin-stimulated adenylate cyclase activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-159	5-hydroxytryptamine receptor 1A	Homo sapiens	298-304	
8200427-1	1994	The purpose of this study was to determine the effects of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide (8-OH-DPAT), on respiratory activity (phrenic nerve activity) following application to the ventral medullary surface in the cat.	8-Hydroxy-2-(di-n-propylamino)tetralin	87-138	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77	
8200427-1	1994	The purpose of this study was to determine the effects of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin hydrobromide (8-OH-DPAT), on respiratory activity (phrenic nerve activity) following application to the ventral medullary surface in the cat.	8-Hydroxy-2-(di-n-propylamino)tetralin	140-149	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77	
7548638-5	1994	Also the selectivity of 8-OH-DPAT for the 5-HT1A receptor is accounted for.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Homo sapiens	42-57	
8008244-4	1994	Because pindolol blocked the effect of 5-HT and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) mimicked the effect of 5-HT, the inhibitory effect of 5-HT appeared to be mediated via the 5-HT1A receptor.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	190-205	
8199879-2	1994	After masking 5-HT1A receptors by 0.1 microM 8-OH-DPAT, the binding displaced by 0.1 microM 5-CT presumably represented 5-HT1D sites and the remaining binding 5-HT1E sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	45-54	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20	
8199864-7	1994	Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P > 0.9).	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34	
8199864-7	1994	Treatment with the 5-HT1A receptor antagonist, NAN-190, administered 15 min before 8-OH-DPAT injection prevented the inhibitory effect of 8-OH-DPAT (100.9 +/- 6.0% vs. controls, P > 0.9).	8-Hydroxy-2-(di-n-propylamino)tetralin	138-147	5-hydroxytryptamine receptor 1A	Homo sapiens	19-34	
8461029-4	1993	For both radioligands the binding sites labelled have the properties of 5HT1A receptors and most antagonists show roughly equal affinities for the receptors labelled by either [3H]8-OH-DPAT or [3H]spiperone.	8-Hydroxy-2-(di-n-propylamino)tetralin	180-189	5-hydroxytryptamine receptor 1A	Homo sapiens	72-77	
8005619-9	1993	Since no known cell line contains the serotonin 5-HT1A receptor (5-HT1A-R), stable transfection of the selected cell lines with a DNA construct encoding the human 5-HT1A-R was carried out and this resulted in a late increase of [3H] 8-OH-DPAT binding in the stationary phase only in the cell lines of neural origin.	8-Hydroxy-2-(di-n-propylamino)tetralin	233-242	5-hydroxytryptamine receptor 1A	Homo sapiens	163-171	
8497336-7	1993	These effects were similar to those produced by the tricyclic antidepressant desipramine and the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103	
8301575-4	1994	The spontaneous tail-flicks, flat-body posture and hypothermia mediated by an action of the 5-HT1A agonist 8-OH-DPAT at postsynaptic 5-HT1A receptors were dose-dependently and completely antagonized by S 14489, S 15535 and S15931 at doses of 0.63 to 10.0 and 2.5 to 40.0 mg/kg for s.c. and oral administration, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
8301575-4	1994	The spontaneous tail-flicks, flat-body posture and hypothermia mediated by an action of the 5-HT1A agonist 8-OH-DPAT at postsynaptic 5-HT1A receptors were dose-dependently and completely antagonized by S 14489, S 15535 and S15931 at doses of 0.63 to 10.0 and 2.5 to 40.0 mg/kg for s.c. and oral administration, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	133-139	
8101137-1	1993	This study examined the effects of kainic acid and NMDA microinjections into the lateral tegmental field on the sympatholytic effect of the 5-HT1A agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	155-164	5-hydroxytryptamine receptor 1A	Homo sapiens	140-146	
8098761-8	1993	Furthermore, (-)penbutolol, but not its (+)antipode, prevented the decrease of 5-HT release induced by the 5-HT1A receptor agonist (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin.	8-Hydroxy-2-(di-n-propylamino)tetralin	131-175	5-hydroxytryptamine receptor 1A	Homo sapiens	107-122	
8490207-12	1993	Next we found that the 5-HT1A agonist 8-OH-DPAT, and to a lesser extent the 5-HT1A-1B agonist RU 24969, mimicked the effects of quipazine during the subjective daytime, whereas the 5-HT1A antagonist NAN-190 blocked quipazine"s effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-47	5-hydroxytryptamine receptor 1A	Homo sapiens	23-29	
8459396-12	1993	Overall, the SAR study showed that cis C-1 substitution maintains the 5-HT1A agonist activity of 8-OH-DPAT whereas trans C-1 substitution displays somewhat diminished activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76	
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	37-75	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28	
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28	
8382063-4	1993	Full inhibition was observed with 5-HT1A receptor agonists: N,N-dipropyl-8-hydroxy-2-aminotetralin (8-OH-DPAT) and flesinoxan, and non-selective 5-HT receptor agonists: d-lysergic acid diethylamide (d-LSD), RU 24,969, bufotenine, methysergide and tryptamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	100-109	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49	
1468487-4	1992	The compound was found to counteract, in a stereospecific fashion, not only the behavioural and hypothermic but also the in vivo 5-HT synthesis/turnover-reducing effects of the specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	210-248	5-hydroxytryptamine receptor 1A	Homo sapiens	186-201	
7870936-5	1993	During combination tests, the selective 5HT1A agonist, 8-OH-DPAT (0.001-3.2 mg/kg), dose-dependently attenuated the discriminative stimulus effects of 5.6 mg/kg U50,488 and 3.2 mg/kg spiradoline.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-64	5-hydroxytryptamine receptor 1A	Homo sapiens	40-45	
1468487-4	1992	The compound was found to counteract, in a stereospecific fashion, not only the behavioural and hypothermic but also the in vivo 5-HT synthesis/turnover-reducing effects of the specific 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	250-259	5-hydroxytryptamine receptor 1A	Homo sapiens	186-201	
8381359-2	1993	In vivo, S 15535 (0.16-10 mg/kg s.c.) acted as an antagonist at postsynaptic 5-HT1A receptors in completely blocking the flat-body posture and hypothermia elicited by the 5-HT1A receptor agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	196-205	5-hydroxytryptamine receptor 1A	Homo sapiens	77-83	
8430834-13	1993	Radioligand binding studies with the specific 5-HT1A receptor ligand [3H]8-OH-DPAT confirmed the presence of 5-HT1A receptor binding sites in bulk-isolated rat medullary TAL.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	46-61	
8430834-13	1993	Radioligand binding studies with the specific 5-HT1A receptor ligand [3H]8-OH-DPAT confirmed the presence of 5-HT1A receptor binding sites in bulk-isolated rat medullary TAL.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	109-124	
7680787-4	1993	Serotonin release was reduced by the systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	92-130	5-hydroxytryptamine receptor 1A	Homo sapiens	68-83	
7680787-4	1993	Serotonin release was reduced by the systemic administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	132-141	5-hydroxytryptamine receptor 1A	Homo sapiens	68-83	
1387027-10	1992	BMY 7378 (8 mg kg-1, s.c.) inhibited another effect of activation of postsynaptic 5-HT1A receptors, i.e., the induction of components of the 5-HT syndrome by 8-OH-DPAT (0.5, 1.0 mg kg-1, s.c.) which suggests that BMY 7378 has antagonistic as well as agonistic effects at these sites.	8-Hydroxy-2-(di-n-propylamino)tetralin	158-167	5-hydroxytryptamine receptor 1A	Homo sapiens	82-88	
1357094-6	1992	The selective 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin at 0.1 microM did not modify the electrically evoked release of [3H]5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	38-76	5-hydroxytryptamine receptor 1A	Homo sapiens	14-29	
1446239-10	1992	Iontophoretic application of the 5HT1A agonists, 8-OH-DPAT and ipsapirone, mimic the suppressive action of serotonin in a dose-dependent manner.	8-Hydroxy-2-(di-n-propylamino)tetralin	49-58	5-hydroxytryptamine receptor 1A	Homo sapiens	33-38	
1448178-2	1992	A transfected clonal cell line which expresses 900 +/- 36 fmol 5-HT1A receptor/mg protein (designated CHO-5-HT1A/WT-27) responded to 5-HT and/or 8-OH-DPAT by coupling to several second messenger pathways.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Homo sapiens	63-78	
1448178-2	1992	A transfected clonal cell line which expresses 900 +/- 36 fmol 5-HT1A receptor/mg protein (designated CHO-5-HT1A/WT-27) responded to 5-HT and/or 8-OH-DPAT by coupling to several second messenger pathways.	8-Hydroxy-2-(di-n-propylamino)tetralin	145-154	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69	
1426017-1	1992	The affinities of a range of antipsychotic drugs at human hippocampal 5-HT1A receptors, defined by specific [3H]8-OH-DPAT binding, were determined.	8-Hydroxy-2-(di-n-propylamino)tetralin	112-121	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76	
1436121-0	1992	Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase.	8-Hydroxy-2-(di-n-propylamino)tetralin	62-71	5-hydroxytryptamine receptor 1A	Homo sapiens	25-31	
1436390-0	1992	Desensitization of 5-HT1A autoreceptors by chronic administration of 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	19-25	
1436390-1	1992	The function of 5-HT1A autoreceptors was examined by measuring the ability of the 5-HT1A receptor agonist 8-OH-DPAT to reduce 5-HT release in the striatum using in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Homo sapiens	16-22	
1436390-1	1992	The function of 5-HT1A autoreceptors was examined by measuring the ability of the 5-HT1A receptor agonist 8-OH-DPAT to reduce 5-HT release in the striatum using in vivo microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	106-115	5-hydroxytryptamine receptor 1A	Homo sapiens	82-97	
1356248-3	1992	Completely analogous effects were found at the somatodendritic 5-HT1A autoreceptor in the raphe nuclei, mediating inhibition of the synthesis of serotonin (5-HT); the full agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the partial agonist, buspirone were utilized to inhibit the synthesis of 5-HT, as measured by changes in levels of L-5-hydroxytryptophan (5-HTP).	8-Hydroxy-2-(di-n-propylamino)tetralin	181-219	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69	
1409788-0	1992	The 5-HT1A agonist 8-OH-DPAT attenuates the satiating action of cholecystokinin.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
1356248-3	1992	Completely analogous effects were found at the somatodendritic 5-HT1A autoreceptor in the raphe nuclei, mediating inhibition of the synthesis of serotonin (5-HT); the full agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the partial agonist, buspirone were utilized to inhibit the synthesis of 5-HT, as measured by changes in levels of L-5-hydroxytryptophan (5-HTP).	8-Hydroxy-2-(di-n-propylamino)tetralin	221-230	5-hydroxytryptamine receptor 1A	Homo sapiens	63-69	
1389001-2	1992	In the present study the excitatory action of nicotine was inhibited by treatment with the selective 5-HT re-uptake inhibitor citalopram or the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	168-177	5-hydroxytryptamine receptor 1A	Homo sapiens	144-159	
1316283-5	1992	The phase advance induced by 8-OH-DPAT was blocked by pretreatment with (-)-pindolol, a 5-HT1A receptor antagonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Homo sapiens	88-103	
1535691-4	1992	The pharmacological profiles of the binding (determined with [3H]8-OH-DPAT) and the calcium response (measured using Fura-2) were clearly of the 5-HT1A type.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-74	5-hydroxytryptamine receptor 1A	Homo sapiens	145-151	
1531359-1	1992	The purported serotonin (5-HT)1A antagonists BMY-7378 and NAN-190 were examined in pigeons for their potential to block the effects of the prototypical 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on punished ("conflict") and unpunished behavior and for their binding affinity at the 5-HT1A receptor site labeled by [3H]-8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	167-205	5-hydroxytryptamine receptor 1A	Homo sapiens	152-158	
1410132-5	1992	In the tail-flick analgesiometric test, administration of the 5-HT1A agonists 8-OH-DPAT and ipsapirone and the 5-HT1B agonists RU24969 and mCPP resulted in a significant dose-dependent increase in tail-flick latencies when compared to predrug baseline values, indicating a decrease in nociceptive sensitivity to noxious thermal stimuli.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Homo sapiens	62-68	
1318516-3	1992	The 5-HT1A receptor agonist, 8-OH-DPAT, and the adenyl cyclase activator, forskolin administered together, produced an additive hyperalgesia, suggesting that the 5-HT1A receptor in peripheral terminals of the primary afferent neurons is positively coupled to the cAMP second messenger system in producing hyperalgesia.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Homo sapiens	162-177	
1839567-6	1991	Both the nonselective 5-HT agonist 5-MeODMT (1.25 mg/kg) and the more selective 5-HT1A agonist 8-OH-DPAT (2 mg/kg) disrupted spontaneous alternation.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-104	5-hydroxytryptamine receptor 1A	Homo sapiens	80-86	
11224080-6	1991	Chronic administration of 8-OH-DPAT resulted in a heightened sensitivity not only to the 5-HT(1A) agonists 8-OH-DPAT and buspirone, but also to what appear to be partial agonist effects of pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	26-35	5-hydroxytryptamine receptor 1A	Homo sapiens	89-96	
11224080-6	1991	Chronic administration of 8-OH-DPAT resulted in a heightened sensitivity not only to the 5-HT(1A) agonists 8-OH-DPAT and buspirone, but also to what appear to be partial agonist effects of pindolol.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	89-96	
11224080-7	1991	This approach represents a first step in the in vivo characterization of changes in 5-HT(1A) sensitivity after chronic administration of 8-OH-DPAT using the drug discrimination procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	137-146	5-hydroxytryptamine receptor 1A	Homo sapiens	84-91	
1819150-6	1991	In contrast, the selective 5-HT1A receptor agonists 8-OH-DPAT and flesinoxan decrease blood pressure and heart rate by a centrally-mediated decrease in sympathetic tone and an increase in vagal tone.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Homo sapiens	27-42	
1838579-4	1991	In competition studies, the rank order of drug affinities was suggestive of a 5-HT1A binding site: 5-HT greater than 8-OH-DPAT, RU24969 greater than methysergide, methiothepin, 1-2,5-dimethoxy-4-iodophenyl aminopropane (DOI), ketanserin greater than mianserin.	8-Hydroxy-2-(di-n-propylamino)tetralin	117-126	5-hydroxytryptamine receptor 1A	Homo sapiens	78-84	
1667606-8	1991	The regional distribution of 5-HT1A receptors labelled by [3H]rauwolscine is in agreement with previous studies using [3H]8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	122-131	5-hydroxytryptamine receptor 1A	Homo sapiens	29-35	
1762063-7	1991	Drug-appropriate responding occurred in pigeons trained at the lower dose of imipramine with the 5-HT1A compounds 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide and gepirone; partial substitution occurred in pigeons trained with the higher dose of imipramine.	8-Hydroxy-2-(di-n-propylamino)tetralin	114-165	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103	
11224080-0	1991	Modification of the discriminative stimulus effects of 8-OH-DPAT, buspirone and the beta-adrenoreceptor antagonist pindolol after chronic administration of the 5-HT(1A) agonist 8-OH-DPAT in the pigeon.	8-Hydroxy-2-(di-n-propylamino)tetralin	177-186	5-hydroxytryptamine receptor 1A	Homo sapiens	160-167	
1664803-1	1991	The aim of the present study was to assess the effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan in ring preparations of human basilar artery.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-124	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77	
1664803-1	1991	The aim of the present study was to assess the effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and flesinoxan in ring preparations of human basilar artery.	8-Hydroxy-2-(di-n-propylamino)tetralin	126-135	5-hydroxytryptamine receptor 1A	Homo sapiens	62-77	
1664803-9	1991	We conclude from the relative rank order of antagonist potency that 8-OH-DPAT and 5-HT produce contraction of the human basilar artery by activation of the same receptor, a 5-HT1-like receptor distinct from the 5-HT1A receptor subtype.	8-Hydroxy-2-(di-n-propylamino)tetralin	68-77	5-hydroxytryptamine receptor 1A	Homo sapiens	211-226	
1658007-1	1991	1 We have examined the actions of the 5-HT1A-receptor ligand 8-OH-DPAT at alpha 2-adrenoceptor ligand binding sites in human platelet and rat kidney membranes and at functional pre- and postjunctional alpha 2-adrenoceptors in rat atrium and human saphenous vein, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	38-53	
1715390-2	1991	Administration of 8-OH-DPAT, a 5-HT1A receptor agonist that decreases 5-HT neuronal activity, decreased extracellular 5-HT in both brain areas.	8-Hydroxy-2-(di-n-propylamino)tetralin	18-27	5-hydroxytryptamine receptor 1A	Homo sapiens	31-46	
1829231-2	1991	The selective 5-HT1A agonist 8-OH-DPAT (0.03-1.0 mg/kg) resulted in dose-dependent increases in responding on the key correlated with imipramine administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	29-38	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20	
1834306-1	1991	Quantitative autoradiographic analysis of serotonin 5-HT1A receptors in the human brain, using [3H]8-OH-DPAT as a ligand, reveals region-specific decreases in receptor labeling with age in several cortical and hippocampal regions and in the raphe nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	52-58	
1683291-7	1991	Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99	
1683291-7	1991	Similarly we have previously observed spiperone reversal of the sympatholytic effects of the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin) but failed to affect nerve activity when given alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-157	5-hydroxytryptamine receptor 1A	Homo sapiens	93-99	
1772068-12	1991	Hyperpolarizing responses are also elicited by the 5-HT1A agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57	
1886079-2	1991	In our attempt to develop new agents that would interact selectively at certain 5-HT receptors, especially the 5-HT1A subtype, 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT) served as a template for the design of novel agents sharing aspects of the pharmacophore of 8-OH-DPAT and 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-164	5-hydroxytryptamine receptor 1A	Homo sapiens	111-117	
1834090-1	1991	The density of 5-HT1A binding using 3H-8-hydroxy-2-(di-n-propyl-amino) tetralin (8-OH-DPAT) as binding ligand, was studied in human frontal cortex of suicide victims and normal controls who died due to medical disease or accidentally.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-90	5-hydroxytryptamine receptor 1A	Homo sapiens	15-21	
1886079-2	1991	In our attempt to develop new agents that would interact selectively at certain 5-HT receptors, especially the 5-HT1A subtype, 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT) served as a template for the design of novel agents sharing aspects of the pharmacophore of 8-OH-DPAT and 5-HT.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine receptor 1A	Homo sapiens	111-117	
1886079-3	1991	5-HT contains no center of asymmetry, and 8-OH-DPAT shows only very modest stereospecificity for 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103	
1886079-4	1991	To develop agents having enhanced potency and selectivity for the 5-HT1A site, several ring systems offering enhanced conformational rigidity which approximate the oxygen to nitrogen interatomic distances of 8-OH-DPAT and (to a lesser extent) 5-HT were synthesized.	8-Hydroxy-2-(di-n-propylamino)tetralin	208-217	5-hydroxytryptamine receptor 1A	Homo sapiens	66-72	
2178032-3	1990	The reductions of GABA-depolarizations which were produced by 1.0 microM 5-HT were mimicked by the 5-HT1A agonists 8-OH-DPAT (8-hydroxy-2-(n-dipropylamino)tetralin) and ipsapirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	115-124	5-hydroxytryptamine receptor 1A	Homo sapiens	99-105	
1824956-4	1991	The [3H]8-OH-DPAT bindings to the prefrontal cortex and hippocampus were potently inhibited by serotonin (IC50 = 6.3 x 10(-9) M) and 5-HT1A agonists (IC50 = 5.0 x 10(-9) - 2.3 x 10(-7) M), while other neurotransmitters, 5-HT2 and 5-HT3 related compounds did not inhibit the binding (IC50 greater than 10(-5) M).	8-Hydroxy-2-(di-n-propylamino)tetralin	8-17	5-hydroxytryptamine receptor 1A	Homo sapiens	133-139	
2052135-3	1991	In 1983 the very selective, high affinity 5-HT1A agonist 8-OH-DPAT was developed which allowed the pharmacology and distribution of the 5-HT1A receptor in the central nervous system of the rat and man to be extensively characterized.	8-Hydroxy-2-(di-n-propylamino)tetralin	57-66	5-hydroxytryptamine receptor 1A	Homo sapiens	136-151	
1825686-5	1991	The 5-HT1A receptor agonist 8-OH-DPAT competitively inhibited carbachol-stimulated inositol phospholipid breakdown with pA2 values of 5.78 (IMR-32) and 5.61 (SK-N-MC).	8-Hydroxy-2-(di-n-propylamino)tetralin	28-37	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
1828519-1	1991	The 5-HT1A receptor agonists buspirone and 8-OH-DPAT have strong effects on serotoninergic systems.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
2178032-6	1990	The presumptive 5-HT1A receptor-mediated effects of 1.0 microM 5-HT and 8-OH-DPAT appeared to result from a direct action on afferent terminals because the reduction of GABA responses was unchanged by addition of TTX to the Ringer"s solution.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-81	5-hydroxytryptamine receptor 1A	Homo sapiens	16-31	
2117776-5	1990	The effects of serotonin on baseline and IL-2-activated NK cells were mimicked by the 5-HT1A receptor-specific agonists 8-OH-DPAT and (+)-ALK.	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Homo sapiens	86-101	
2136217-2	1990	The putative 5-HT1A receptor agonists buspirone, gepirone, ipsapirone and 8-OH-DPAT all produced anxiolytic-like effects in narrow low dose-ranges, while in higher doses the behavior returned towards that seen in controls and, after the highest doses of buspirone and gepirone, was suppressed below that of controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28	
2078274-17	1990	Hyperpolarizing responses are also elicited by the 5-HT1A agonists, 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) and 5-carboxyamidotryptamine.	8-Hydroxy-2-(di-n-propylamino)tetralin	104-113	5-hydroxytryptamine receptor 1A	Homo sapiens	51-57	
2140514-5	1990	Using acutely isolated, patch-clamped dorsal raphe neurons, we found that low concentrations of 5-HT and the 5-HT1A-selective agonist 8-OH-DPAT reversibly decrease whole-cell calcium current.	8-Hydroxy-2-(di-n-propylamino)tetralin	134-143	5-hydroxytryptamine receptor 1A	Homo sapiens	109-115	
2138222-4	1990	8-OH-DPAT (0.0625-4.0 micrograms) produced dose-dependent hypotension and bradycardia, which were antagonized by the 5-HT1A antagonists spiperone and spiroxatrine.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	117-123	
1970424-6	1990	The increase in the behavioural deficit induced by 8-OH-DPAT, was likely to have resulted from stimulation of 5-HT1A receptors, since it was impaired by pretreatment with penbutolol, a beta-adrenergic-blocking drug, also known to bind to 5-HT1 receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	110-116	
1702490-3	1990	However, the central sympathoinhibition observed with 5-HT1A agonists such as 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is not uniform for all regional sympathetic outflows, renal outflow being the most sensitive.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-87	5-hydroxytryptamine receptor 1A	Homo sapiens	54-60	
1968842-0	1990	Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapirone in vitro.	8-Hydroxy-2-(di-n-propylamino)tetralin	75-84	5-hydroxytryptamine receptor 1A	Homo sapiens	59-65	
1702490-3	1990	However, the central sympathoinhibition observed with 5-HT1A agonists such as 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is not uniform for all regional sympathetic outflows, renal outflow being the most sensitive.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-127	5-hydroxytryptamine receptor 1A	Homo sapiens	54-60	
2530993-1	1989	The influence of the centrally active 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on the exploration of objects was studied in hamsters, using a radioactographic method.	8-Hydroxy-2-(di-n-propylamino)tetralin	53-91	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44	
25363799-2	2015	EXPERIMENTAL APPROACH: In vitro studies investigated the effect of THCV on targeting by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) of 5-HT1A receptors in membranes obtained from rat brainstem or human 5-HT1A CHO cells, using [(35)S]-GTPgammaS and 8-[(3)H]-OH-DPAT binding assays.	8-Hydroxy-2-(di-n-propylamino)tetralin	128-137	5-hydroxytryptamine receptor 1A	Homo sapiens	209-215	
2530993-1	1989	The influence of the centrally active 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) on the exploration of objects was studied in hamsters, using a radioactographic method.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-102	5-hydroxytryptamine receptor 1A	Homo sapiens	38-44	
2481192-10	1989	These results establish that the 5-HT1A receptor agonists flesinoxan and 8-OH-DPAT elicited a systemic and regional hemodynamic profile that differs from that of the alpha 2-adrenoceptor agonist clonidine.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48	
2574684-2	1989	Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	78-117	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43	
2533325-4	1989	In addition, 5-HT1A and 5-HT1C sites were directly visualized with the more selective radioligands [3H]8-OH-DPAT and [3H]mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	103-112	5-hydroxytryptamine receptor 1A	Homo sapiens	13-19	
2529951-1	1989	Previous studies indicate that the selective 5-HT1A agonist, 8-OH DPAT, acts in the central nervous system to inhibit sympathetic nerve activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	45-51	
2529951-12	1989	Rather, the data suggest that 8-OH DPAT acts postsynaptically on 5-HT1A receptors located on central sympathetic neurons to inhibit sympathetic nerve activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	65-71	
2574684-2	1989	Indicative of anxiolytic effects the 5-HT1A agonists, buspirone, gepirone and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) all significantly increased social interaction time and open arm exploration time in the social interaction and elevated plus maze procedures, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	119-128	5-hydroxytryptamine receptor 1A	Homo sapiens	37-43	
2702482-9	1989	Regularly firing neurons were completely inhibited by low doses of the 5-HT1A agonist 8-hydroxy-dipropylamino-tetralin (8-OH-DPAT) (i.e. 2 micrograms/kg, i.v.)	8-Hydroxy-2-(di-n-propylamino)tetralin	120-129	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77	
2575564-4	1989	The central 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produced hypotension and decreases in sympathetic nerve activity (SNA).	8-Hydroxy-2-(di-n-propylamino)tetralin	36-75	5-hydroxytryptamine receptor 1A	Homo sapiens	12-27	
2575564-4	1989	The central 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) produced hypotension and decreases in sympathetic nerve activity (SNA).	8-Hydroxy-2-(di-n-propylamino)tetralin	77-86	5-hydroxytryptamine receptor 1A	Homo sapiens	12-27	
2533356-1	1989	The repeated administration of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg, twice daily for 14 days) significantly diminished hypothermia and corticosterone secretion induced by an acute challenge with the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg) when compared to the responses in animals treated chronically with the solvent vehicle.	8-Hydroxy-2-(di-n-propylamino)tetralin	229-238	5-hydroxytryptamine receptor 1A	Homo sapiens	214-220	
2533356-5	1989	These data are consistent with other evidence that these physiological effects of 8-OH-DPAT and MK-212 are mediated by 5-HT1A and 5-HT2 receptors, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	82-91	5-hydroxytryptamine receptor 1A	Homo sapiens	119-145	
2732950-6	1989	The selective 5-HT1A agonist, 8-hydroxy-2(di-n-propylamino)tetralin, was the least potent but elicited a more intense vasoconstriction.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-67	5-hydroxytryptamine receptor 1A	Homo sapiens	14-20	
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49	
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-97	5-hydroxytryptamine receptor 1A	Homo sapiens	34-40	
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	34-49	
2643854-2	1989	Results from experiments with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) suggest that activation of somatodendritic 5-HT1A receptors in the medulla oblongata decreases the firing of serotoninergic neurons and thus reduces their excitatory input to the sympathetic neurons in the intermediolateral cell column.	8-Hydroxy-2-(di-n-propylamino)tetralin	99-108	5-hydroxytryptamine receptor 1A	Homo sapiens	34-40	
2969339-3	1988	spiperone, but not LY53837 (a 5-HT2 antagonist), antagonized the inhibition induced by 5-HT1A agonists 8-hydroxy-dipropylaminotetralin (8-OH-DPAT) and buspirone in the dorsal raphe nucleus.	8-Hydroxy-2-(di-n-propylamino)tetralin	136-145	5-hydroxytryptamine receptor 1A	Homo sapiens	87-93	
2905470-1	1988	Under several behavioral procedures, such as punished responding and drug discrimination, the effects of the atypical anxiolytic buspirone are similar to those of its analogue gepirone, and to those of the 5-HT1A receptor agonist 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	230-239	5-hydroxytryptamine receptor 1A	Homo sapiens	206-221	
2975354-6	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103	
2471984-7	1989	Acute administration of the 5-HT1A receptor ligand 8-OH-DPAT (3.0 mg/kg) resulted in large decreases in 5-HIAA levels that persisted throughout the period of chronic administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43	
2521959-2	1989	5-HT1A and 5-HT1C binding sites were pharmacologically blocked using 100 nM 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) and 100 nM mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-114	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6	
2521959-2	1989	5-HT1A and 5-HT1C binding sites were pharmacologically blocked using 100 nM 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) and 100 nM mesulergine, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-125	5-hydroxytryptamine receptor 1A	Homo sapiens	0-6	
2535033-5	1989	5HT-1A receptor sites were detected by displacement experiments and by direct labeling with [3H]8-hydroxy-2(di-n-propylamino) tetralin 8OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-143	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15	
2976673-0	1988	NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	94-132	5-hydroxytryptamine receptor 1A	Homo sapiens	79-85	
2976673-0	1988	NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	134-143	5-hydroxytryptamine receptor 1A	Homo sapiens	79-85	
2958301-4	1987	Two 5-HT1A ligands, LY165163 and 8-OH-DPAT, mimicked the effect of serotonin, although with slower kinetics.	8-Hydroxy-2-(di-n-propylamino)tetralin	33-42	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
2901381-9	1988	The prototype 5HT1A agonist 8OH-DPAT may also have potential anxiolytic effects.	8-Hydroxy-2-(di-n-propylamino)tetralin	28-36	5-hydroxytryptamine receptor 1A	Homo sapiens	14-19	
2961966-0	1988	The 5-HT1A receptor probe [3H]8-OH-DPAT labels the 5-HT transporter in human platelets.	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	4-19	
2889156-6	1987	In contrast the hypothermic response which follows injection of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin-(8-OHDPAT) is attenuated not only after a range of diverse antidepressant drugs but also electroconvulsive shock.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-130	5-hydroxytryptamine receptor 1A	Homo sapiens	68-82	
2889156-6	1987	In contrast the hypothermic response which follows injection of the 5HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)-tetralin-(8-OHDPAT) is attenuated not only after a range of diverse antidepressant drugs but also electroconvulsive shock.	8-Hydroxy-2-(di-n-propylamino)tetralin	132-140	5-hydroxytryptamine receptor 1A	Homo sapiens	68-82	
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-150	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77	
2966310-1	1988	In human caudate and cortex membranes, [3H]serotonin ([3H]5-HT) labels 5-HT1A and 5-HT1C recognition sites which show nanomolar affinity for 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and mesulergine respectively, whereas no 5-HT1B binding could be identified.	8-Hydroxy-2-(di-n-propylamino)tetralin	152-191	5-hydroxytryptamine receptor 1A	Homo sapiens	71-77	
2966310-5	1988	In contrast, these sites showed low affinity for drugs with high affinity and/or selectivity for 5-HT1A (8-OH-DPAT, buspirone), 5-HT1B (21-009, RU 24969), 5-HT1C (mesulergine, mianserin) and 5-HT2 sites (ketanserin, cinanserin).	8-Hydroxy-2-(di-n-propylamino)tetralin	105-114	5-hydroxytryptamine receptor 1A	Homo sapiens	97-103	
2834759-3	1988	Antidepressant treatments also attenuate the temperature response to the 5-HT1A agonist 8-OH-DPAT but 5-HT2-receptor number and function are both decreased by antidepressant drugs but increased by ECS.	8-Hydroxy-2-(di-n-propylamino)tetralin	88-97	5-hydroxytryptamine receptor 1A	Homo sapiens	73-79	
3119155-3	1987	A hyperpolarization associated with an increased conductance state and insensitive to 5-HT2 antagonists was observed in 26% of the neurons and could be mimicked by the selective 5-HT1A agonist (+/-)-8-hydroxy-2-(di-N-propyl-amino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	194-238	5-hydroxytryptamine receptor 1A	Homo sapiens	178-184	
3119155-3	1987	A hyperpolarization associated with an increased conductance state and insensitive to 5-HT2 antagonists was observed in 26% of the neurons and could be mimicked by the selective 5-HT1A agonist (+/-)-8-hydroxy-2-(di-N-propyl-amino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	240-249	5-hydroxytryptamine receptor 1A	Homo sapiens	178-184	
2887435-6	1987	The similar stimulus properties of 8-OHDPAT and the novel anxiolytics (buspirone, ipsapirone) are mirrored by the common abilities of these agents to selectively inhibit 5-HT1A binding and release punished responding.	8-Hydroxy-2-(di-n-propylamino)tetralin	35-43	5-hydroxytryptamine receptor 1A	Homo sapiens	170-176	
3025366-3	1987	The 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin did not cause stimulation.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-56	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
3496228-6	1987	The corresponding values for the 5HT1A selective agonists 8-OH-DPAT and ipsapirone were 1.3 and 33 nmol/kg.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Homo sapiens	33-38	
3720831-4	1986	The tetralin derivative 8-OH-DPAT, a drug with selective affinity for 5-HT1A binding sites, was a weak partial agonist on veins and completely devoid of any activity on the platelets.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76	
3013203-0	1986	Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(DI-n-propylamino)tetralin ([3H]-8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	115-129	5-hydroxytryptamine receptor 1A	Homo sapiens	29-35	
3013203-1	1986	Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Homo sapiens	41-62	
3013203-1	1986	Nucleotide interactions were examined at 5-hydroxytryptamine1A (5-HT1A) binding sites labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).	8-Hydroxy-2-(di-n-propylamino)tetralin	142-151	5-hydroxytryptamine receptor 1A	Homo sapiens	64-70	
2942782-2	1986	5-HT and the preferential 5-HT1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] concentration-dependently inhibited the evoked 3H overflow.	8-Hydroxy-2-(di-n-propylamino)tetralin	50-59	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41	
2942782-2	1986	5-HT and the preferential 5-HT1A receptor agonist 8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] concentration-dependently inhibited the evoked 3H overflow.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-99	5-hydroxytryptamine receptor 1A	Homo sapiens	26-41	
32315693-0	2020	Administration of low doses of the 5-HT1A receptor agonist 8-OH-DPAT attenuates the discriminative signal of amphetamine in the conditioned taste aversion procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	35-50	
33384591-6	2020	The [3H]-8-OH-DPAT binding assay was used to determine the pharmacological interaction of CBD with 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	9-18	5-hydroxytryptamine receptor 1A	Homo sapiens	99-105	
32396921-5	2020	The results show that intra-mPFC infusion of the 5-HT1A receptor agonist 8-OH-DPAT induces rapid and long-lasting antidepressant-like effects in the forced swim, novelty-suppressed feeding, female urine sniffing, and chronic unpredictable stress tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	49-64	
32315693-4	2020	Additionally, to establish a correlation between the behavioral effects in drug discrimination and changes in dopamine (DA) and gamma-aminobutyric acid (GABA) concentrations, we evaluated the effect of systemic administration of low or high doses of the 5-HT1A receptor agonist 8-OH-DPAT and of the 5-HT1A receptor antagonist WAY100135 on DA and GABA extracellular concentrations in the nucleus accumbens (nAcc) and ventral tegmental area (VTA), respectively, using cerebral microdialysis.	8-Hydroxy-2-(di-n-propylamino)tetralin	278-287	5-hydroxytryptamine receptor 1A	Homo sapiens	254-269	
32315693-1	2020	Several studies have reported that low doses of the 5-HT1A receptor agonist 8-OH-DPAT reduce cocaine-induced locomotor activity.	8-Hydroxy-2-(di-n-propylamino)tetralin	76-85	5-hydroxytryptamine receptor 1A	Homo sapiens	52-67	
32315693-3	2020	This study aimed to evaluate the effects of low and high doses of the 5-HT1A agonist 8-OH-DPAT on the discriminative signal of AMPH using conditioned taste aversion as a drug discrimination procedure.	8-Hydroxy-2-(di-n-propylamino)tetralin	85-94	5-hydroxytryptamine receptor 1A	Homo sapiens	70-76	
26876117-6	2016	Interestingly, co-incubation of heterodimer-expressing HEK 293 cells with clozapine and the 5-HT1 A R agonist 8-OH DPAT potentiated post-synaptic effects, especially with respect to ERK activation.	8-Hydroxy-2-(di-n-propylamino)tetralin	110-119	5-hydroxytryptamine receptor 1A	Homo sapiens	92-99	
31289857-4	2019	The 5-HT1A agonist 8-OH-DPAT (0.0125-0.1 mg/kg subcutaneous) increased impulsive action at low doses, but decreased it at higher doses, on the novel paced variable consecutive number with discriminative stimulus task (VCN).	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	4-10	
31289857-7	2019	We hypothesize that the biphasic effect of 8-OH-DPAT is due to actions on presynaptic raphe 5-HT1A autoreceptors, and also postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
31289857-7	2019	We hypothesize that the biphasic effect of 8-OH-DPAT is due to actions on presynaptic raphe 5-HT1A autoreceptors, and also postsynaptic 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	43-52	5-hydroxytryptamine receptor 1A	Homo sapiens	136-142	
30858018-6	2019	Likewise, intra-dlPAG injection of the 5-HT1A receptor agonist 8-OH-DPAT (3.2 nmol/0.2 u L) also reduced anxiety-like behavior, a response prevented by intra-dlPAG injection of AM251 (100 pmol/0.2 microL).	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Homo sapiens	39-54	
29660440-6	2018	5-HT1A receptor function, as measured by quantitative autoradiography of 8-OH-DPAT (1 muM)-stimulated [35S]GTPgammaS binding, was markedly reduced in hippocampus of weanling female, but not male offspring (postnatal day, PND 21) of dams fed the low protein diet.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15	
29730825-13	2018	Although 18F-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
29730825-13	2018	Although 18F-F13640 in vivo binding was blocked by the 5-HT1A antagonist WAY-100635 and the 5-HT1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT1A receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	107-116	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
29339052-2	2018	To provide more detailed information on the processes underlying the alleviation of dyskinesia, we have here investigated changes in the spectral contents of local field potentials in cortico-basal ganglia-thalamic circuits following treatment with this novel group of 5-HT1A agonists or the prototypical agonist, 8-OH-DPAT.	8-Hydroxy-2-(di-n-propylamino)tetralin	314-323	5-hydroxytryptamine receptor 1A	Homo sapiens	269-275	
28347824-10	2017	Association of ineffective doses of Nor-BNI and the 5-HT1A-R agonist 8-OH-DPAT caused panicolytic-like effect in these two tests.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	52-58	
26612522-4	2016	An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	159-198	5-hydroxytryptamine receptor 1A	Homo sapiens	105-111	
26612522-4	2016	An approach that has undergone considerable empirical research after TBI is pharmacological targeting of 5-HT1A receptors with agonists such as repinotan HCl, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), and buspirone.	8-Hydroxy-2-(di-n-propylamino)tetralin	200-209	5-hydroxytryptamine receptor 1A	Homo sapiens	105-111	
30347827-2	2018	Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	72-128	5-hydroxytryptamine receptor 1A	Homo sapiens	44-59	
30347827-2	2018	Almost all of the studied compounds (except 5-HT1A receptor agonist (2R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT)) exhibited absolute cytotoxic activity against the examined cancer cells.	8-Hydroxy-2-(di-n-propylamino)tetralin	130-139	5-hydroxytryptamine receptor 1A	Homo sapiens	44-59	
29057454-2	2018	EXPERIMENTAL APPROACH: We investigated the effects of HU-580 and CBDA on (i) activation by 8-hydroxy-2-(di-n-propylamino)tetralin of human 5-HT1A receptors in CHO cell membranes, using [35 S]-GTPgammaS binding assays, (ii) gaping by rats in acute and anticipatory nausea models, and (iii) stress-induced anxiety-like behaviour, as indicated by exit time from the light compartment of a light-dark box of rats subjected 24 h earlier to six tone-paired foot shocks.	8-Hydroxy-2-(di-n-propylamino)tetralin	91-129	5-hydroxytryptamine receptor 1A	Homo sapiens	139-145	
26749090-7	2016	DMH treatment with 8-OH-DPAT decreased escape responses, which strongly suggests that the 5-HT1A receptor modulates the defensive responses.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	90-105	
26856853-7	2016	Dose-effect curves for the 5-HT1A-mediated hyperactivity produced by the 5-HT1A agonist, 8-OH-DPAT, and the 5-HT1B-mediated adipsic response produced by RU 24969 were shifted rightward, suggesting a desensitization of 5-HT1A and 5-HT1B receptor mechanisms.	8-Hydroxy-2-(di-n-propylamino)tetralin	89-98	5-hydroxytryptamine receptor 1A	Homo sapiens	27-33	
25304920-5	2014	The purpose of the present study is to determine 5-HT1A receptor-induced G-protein functional activation by 8-OH-DPAT-stimulated [(35)S]GTPgammaS binding assay in hippocampal tissue of surgical patients with mTLE.	8-Hydroxy-2-(di-n-propylamino)tetralin	108-117	5-hydroxytryptamine receptor 1A	Homo sapiens	49-64	
26080602-1	2015	We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Homo sapiens	33-48	
26080602-1	2015	We have found that activation of 5-HT1A receptor with 8-OH-DPAT (0.1, 0.5 and 1.0 mg/kg, i. p.) considerably and dose-dependently reduced the number of 5-HT2A receptor-mediated head-twitches, whereas 5-HT1A receptor blockade with WAY-100635 (0.5 and 1.0 mg/kg, i. p.), on the contrary, pro- duced significant enhancement of this 5-HT2A receptor functional response.	8-Hydroxy-2-(di-n-propylamino)tetralin	54-63	5-hydroxytryptamine receptor 1A	Homo sapiens	200-215	
25687330-4	2015	Unexpectedly, 5-hydroxytryptamine 1A receptor (5-HT1A) agonist 8-OH-DPAT did not decrease forskolin-induced tau hyperphosphorylation.	8-Hydroxy-2-(di-n-propylamino)tetralin	63-72	5-hydroxytryptamine receptor 1A	Homo sapiens	47-53	
25288485-3	2015	Using a pharmacological approach, we found that the 5-HT1A agonist 8-OH-DPAT also potentiated the antidepressant-like effects of cytisine, suggesting that this subtype might mediate the interaction between the serotonergic and cholinergic systems.	8-Hydroxy-2-(di-n-propylamino)tetralin	67-76	5-hydroxytryptamine receptor 1A	Homo sapiens	52-58	
22465320-0	2012	Elucidating the role of 5-HT(1A) and 5-HT(7) receptors on 8-OH-DPAT-induced behavioral recovery after experimental traumatic brain injury.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-67	5-hydroxytryptamine receptor 1A	Homo sapiens	24-31	
24830553-7	2014	Previously, it was shown that Ktl is in a complex with the Drosophila 5-HT receptor 5-HT7, and we observed that both Ktl and the 5-HT1A receptor are required in insulin-producing cells (IPCs) for proper adult male behaviour, as well as for hyperaggressive activity induced by the mammalian 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin-hydrobromide.	8-Hydroxy-2-(di-n-propylamino)tetralin	314-360	5-hydroxytryptamine receptor 1A	Homo sapiens	129-144	
24385311-8	2014	Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibiting 8-OH-DPAT-stimulated (35)S-GTPgammaS binding.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	38-53	
23299041-7	2013	5-HT1A receptor agonist 8-OH-DPAT (0.2 and 0.5mg/kg) decreased aggressive behavior in both A infant and adult rats.	8-Hydroxy-2-(di-n-propylamino)tetralin	24-33	5-hydroxytryptamine receptor 1A	Homo sapiens	0-15	
22735975-5	2012	Food intake was measured in chickens after centrally administered lipopolysaccharide (LPS) (20 ng) (0 h), followed by intracerebroventricular (ICV) injection of the 5-HT(1A) autoreceptor agonist (8-OH-DPAT, 61 nmol), 5-HT(2c) receptor antagonist (SB 242084, 30 nm), and NMDA receptor antagonist (DL-AP5, 5 nm) at the onset of anorexia (4 h).	8-Hydroxy-2-(di-n-propylamino)tetralin	196-205	5-hydroxytryptamine receptor 1A	Homo sapiens	165-172	
24429224-5	2014	The results showed that both clozapine and norclozapine, although with a 20-fold lower affinity, displaced [3H]8-OH-DPAT binding in all of the brain regions analysed, suggesting their interaction with 5-HT(1A) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	111-120	5-hydroxytryptamine receptor 1A	Homo sapiens	201-208	
24157794-4	2013	The findings show that coagonist treatment with 8-OH-DPAT and FGF2 but not treatment with the 5-HT1A agonist alone markedly increases the BRETmax values and significantly reduces the BRET50 values of 5HT1A homodimerization.	8-Hydroxy-2-(di-n-propylamino)tetralin	48-57	5-hydroxytryptamine receptor 1A	Homo sapiens	200-205	
24157794-8	2013	Furthermore, FGF2 alone produced a small increase in the BRET(2) signal from the 5-HT1A-beta-arrestin2 receptor-protein complex which was additive to the marked effect of 8-OH-DPAT alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	171-180	5-hydroxytryptamine receptor 1A	Homo sapiens	81-87	
23354536-4	2013	The response to the 5-HT1a agonist, 8-OHDPAT (0.003-0.5 mg/kg, SC), was assessed using lower lip retraction (LLR), hypoactivity, and 5-hydroxytryptophan (5-HTP) accumulation following decarboxylase inhibition.	8-Hydroxy-2-(di-n-propylamino)tetralin	36-44	5-hydroxytryptamine receptor 1A	Homo sapiens	20-26	
22940695-6	2012	As measured by autoradiography with [(3)H]8-hydroxy-2-(di-n-propyl) aminotetralin (8-OH-DPAT), a decrease of 5-HT(1A) receptor specific binding was observed in the posterior/dorsal region of the anterior cingulate gyrus and posterior/ventral area of the superior frontal gyrus of MPTP monkeys compared to controls.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	109-126	
22465320-1	2012	8-OH-DPAT is a 5-HT(1A/7) receptor agonist that enhances behavioral recovery after traumatic brain injury (TBI).	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	15-22	
22465320-2	2012	This study is a first attempt to decipher whether the benefits induced by 8-OH-DPAT after TBI are mediated by 5-HT(1A) or 5-HT(7) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	74-83	5-hydroxytryptamine receptor 1A	Homo sapiens	110-117	
22465320-9	2012	Evaluation of a specific 5-HT(7) receptor agonist will further elucidate the contribution of 5-HT(1A) and 5-HT(7) receptors on behavioral recovery conferred by acute 8-OH-DPAT treatment after TBI.	8-Hydroxy-2-(di-n-propylamino)tetralin	166-175	5-hydroxytryptamine receptor 1A	Homo sapiens	93-100	
20709144-4	2010	A concentration-related inhibition of withdrawal was observed when methamphetamine-exposed planarians were placed into a solution containing either methamphetamine and 5-HT (0.1-100 muM) or methamphetamine and the 5-HT(1A) receptor agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) (10, 20 muM).	8-Hydroxy-2-(di-n-propylamino)tetralin	240-278	5-hydroxytryptamine receptor 1A	Homo sapiens	214-231	
20656461-4	2011	We show that administration of the 5-HT(1A) receptor agonist 8-OH-DPAT prompts a dose-dependent reduction in local cerebral blood volume (CBV) in brain areas rich in neurons expressing post-synaptic 5-HT(1A) receptor, including the prefrontal cortex, hippocampus and amygdalar nuclei.	8-Hydroxy-2-(di-n-propylamino)tetralin	61-70	5-hydroxytryptamine receptor 1A	Homo sapiens	199-216	
21899601-2	2011	Application of the 5-HT(1A)  receptor (5-HT(1A) R) agonist 8-OH-DPAT was shown (i) to depress cellular cAMP, leading to dephosphorylation of Glyalpha(3) R and augmentation of postsynaptic inhibition of neurons expressing Glyalpha(3) R (Manzke et al., 2010) and (ii) to hyperpolarize respiratory neurons through 5-HT-activated potassium channels.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	19-26	
21899601-2	2011	Application of the 5-HT(1A)  receptor (5-HT(1A) R) agonist 8-OH-DPAT was shown (i) to depress cellular cAMP, leading to dephosphorylation of Glyalpha(3) R and augmentation of postsynaptic inhibition of neurons expressing Glyalpha(3) R (Manzke et al., 2010) and (ii) to hyperpolarize respiratory neurons through 5-HT-activated potassium channels.	8-Hydroxy-2-(di-n-propylamino)tetralin	59-68	5-hydroxytryptamine receptor 1A	Homo sapiens	39-46	
19447286-3	2009	At 24-48 h acutely 8-OH-DPAT (0.062 mg/kg) administration enhanced memory and attenuated mRNA 5-HT(1A)<5-HT(7) receptors expression respect to saline group.	8-Hydroxy-2-(di-n-propylamino)tetralin	19-28	5-hydroxytryptamine receptor 1A	Homo sapiens	94-101	
20488186-6	2010	Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Homo sapiens	39-56	
20488186-6	2010	Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Homo sapiens	151-168	
20488186-6	2010	Xenopus oocytes injected with toadfish 5-HT(1A) receptor cRNA displayed significantly higher binding of [(3)H]5-HT that was abolished by the mammalian 5-HT(1A) receptor agonist, 8-OH-DPAT, indicating a conserved binding site of the toadfish 5-HT(1A) receptor and a high specificity for the agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	178-187	5-hydroxytryptamine receptor 1A	Homo sapiens	151-168	
20802053-2	2010	Opioid-induced ventilatory depression was shown to be counteracted in anesthetized rats by serotonin(1A)-receptor (5-HT(1A)-R)-agonist 8-OH-DPAT, which cannot be applied to humans.	8-Hydroxy-2-(di-n-propylamino)tetralin	135-144	5-hydroxytryptamine receptor 1A	Homo sapiens	115-122	
20450907-0	2010	Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	52-61	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43	
20450907-0	2010	Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43	
20450907-0	2010	Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.	8-Hydroxy-2-(di-n-propylamino)tetralin	96-105	5-hydroxytryptamine receptor 1A	Homo sapiens	28-43	
20450907-1	2010	8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is the prototypical agonist at serotonin 5-HT1A receptors; however, activity at other targets contributes to the functional effects of the compound as well.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-9	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
20450907-1	2010	8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin] is the prototypical agonist at serotonin 5-HT1A receptors; however, activity at other targets contributes to the functional effects of the compound as well.	8-Hydroxy-2-(di-n-propylamino)tetralin	11-49	5-hydroxytryptamine receptor 1A	Homo sapiens	92-98	
20223238-7	2010	In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	141-182	5-hydroxytryptamine receptor 1A	Homo sapiens	114-131	
20223238-7	2010	In the second experiment, the effects of prior treatment with fluoxetine on the lordosis inhibitory effect of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), were studied.	8-Hydroxy-2-(di-n-propylamino)tetralin	184-193	5-hydroxytryptamine receptor 1A	Homo sapiens	114-131	
20520769-9	2010	Concordantly, the administration of 5-HT, 8-OH-DPAT (a specific 5-HT1A receptor agonist), or fluoxetine (a 5-HT reuptake inhibitor) increased tubulin acetylation.	8-Hydroxy-2-(di-n-propylamino)tetralin	42-51	5-hydroxytryptamine receptor 1A	Homo sapiens	64-79	
19913081-8	2010	Only Uncaria hook (3.13-50 microg/ml), of the seven constituent herbal extracts, inhibited the [(3)H]8-OH-DPAT binding to 5-HT1A receptors in a concentration-dependent manner, and the IC(50) value was estimated to be 7.42 microg/ml.	8-Hydroxy-2-(di-n-propylamino)tetralin	101-110	5-hydroxytryptamine receptor 1A	Homo sapiens	122-128	
19447286-7	2009	Together these data revealed that, when both 5-HT(1A) and 5-HT(7) receptors were stimulated by 8-OHDPAT under memory consolidation, subtle changes emerged, not evident at behavioral level though detectable at genes expression.	8-Hydroxy-2-(di-n-propylamino)tetralin	95-103	5-hydroxytryptamine receptor 1A	Homo sapiens	45-52	
18289523-1	2008	The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	215-232	5-hydroxytryptamine receptor 1A	Homo sapiens	67-82	
19075042-3	2009	The 5-HT(1A) receptor agonist, 8-hydroxy-2-dipropylaminotetralin, produced an increase in contractions that was highly variable, of low potency, and was not significantly inhibited by the 5-HT(1A) antagonist WAY100635 [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide].	8-Hydroxy-2-(di-n-propylamino)tetralin	31-64	5-hydroxytryptamine receptor 1A	Homo sapiens	4-21	
18667366-5	2008	In this study we showed that intracisternal injection of a low dose (1 microg/kg) of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), significantly reduced the increases in heart rate and renal sympathetic nerve activity evoked by disinhibition of the DMH, but had no effect on these responses when injected intravenously.	8-Hydroxy-2-(di-n-propylamino)tetralin	116-154	5-hydroxytryptamine receptor 1A	Homo sapiens	89-106	
18622186-0	2008	Behavior selectively elicited by novel stimuli: modulation by the 5-HT1A agonist 8-OHDPAT and antagonist WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	81-89	5-hydroxytryptamine receptor 1A	Homo sapiens	66-72	
18455431-3	2008	In the presence of NMDA, a low concentration of the 5-HT(1A) agonist 8-OH-DPAT substantially reduced the number of spikes, and a low concentration of the 5-HT(2A/C) agonist alpha-Me-5HT significantly enhanced it, while both agonists were ineffective when applied alone.	8-Hydroxy-2-(di-n-propylamino)tetralin	69-78	5-hydroxytryptamine receptor 1A	Homo sapiens	52-59	
18667366-5	2008	In this study we showed that intracisternal injection of a low dose (1 microg/kg) of the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), significantly reduced the increases in heart rate and renal sympathetic nerve activity evoked by disinhibition of the DMH, but had no effect on these responses when injected intravenously.	8-Hydroxy-2-(di-n-propylamino)tetralin	156-165	5-hydroxytryptamine receptor 1A	Homo sapiens	89-106	
18667366-6	2008	Subsequent intracisternal administration of the 5-HT(1A) receptor antagonist WAY-100635 restored the DMH-evoked cardiovascular responses to levels observed before 8-OH-DPAT administration.	8-Hydroxy-2-(di-n-propylamino)tetralin	163-172	5-hydroxytryptamine receptor 1A	Homo sapiens	48-65	
18513131-3	2008	In preclinical studies, it has been demonstrated that R (+)-8-hydroxy-dipropylaminotetralin (8-OHDPAT), a 5-HT1A agonist, has anxiolytic properties.	8-Hydroxy-2-(di-n-propylamino)tetralin	93-101	5-hydroxytryptamine receptor 1A	Homo sapiens	106-112	
18469535-6	2008	The decrease in pLMV induced by the5-HT1A agonist (8-OH-DPAT), and the 5-HT1B/2C agonist (mCPP), was antagonized by pretreatment with the 5-HT1A antagonist (WAY-100635) at a dose that had no effect of its own on pLMV.	8-Hydroxy-2-(di-n-propylamino)tetralin	51-60	5-hydroxytryptamine receptor 1A	Homo sapiens	35-41	
18410179-3	2008	Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a drug that reduces 5-HT release by acting on presynaptic autoreceptors, dose-dependently increased consumption of 0.45 M NaCl in a one-bottle test.	8-Hydroxy-2-(di-n-propylamino)tetralin	58-95	5-hydroxytryptamine receptor 1A	Homo sapiens	41-48	
18410179-3	2008	Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT), a drug that reduces 5-HT release by acting on presynaptic autoreceptors, dose-dependently increased consumption of 0.45 M NaCl in a one-bottle test.	8-Hydroxy-2-(di-n-propylamino)tetralin	97-106	5-hydroxytryptamine receptor 1A	Homo sapiens	41-48	
18269931-6	2008	The results indicate that both NR1 subunit phosphorylation and the neurotrophin BDNF account, at least in part, for the neuroprotective effect of 8-OH-DPAT on cell damage induced by global ischemia in the gerbil hippocampus and support the potential interest of 5-HT1A receptor activation in the search for neuroprotective strategies.	8-Hydroxy-2-(di-n-propylamino)tetralin	146-155	5-hydroxytryptamine receptor 1A	Homo sapiens	262-277	
18094064-3	2008	We previously showed in conscious piglets that activation of 5-HT1A receptors with (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) in the paragigantocellularis lateralis (PGCL), a medullary region lateral to the raphe that contains substantial numbers of 5-HT neurons, eliminates rapid eye movement (REM) sleep and decreases shivering in a cold environment, but does not attenuate peripheral vasoconstriction.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-125	5-hydroxytryptamine receptor 1A	Homo sapiens	61-67	
18094064-3	2008	We previously showed in conscious piglets that activation of 5-HT1A receptors with (+/-)-8-hydroxy-2-(dipropylamino)-tetralin (8-OH-DPAT) in the paragigantocellularis lateralis (PGCL), a medullary region lateral to the raphe that contains substantial numbers of 5-HT neurons, eliminates rapid eye movement (REM) sleep and decreases shivering in a cold environment, but does not attenuate peripheral vasoconstriction.	8-Hydroxy-2-(di-n-propylamino)tetralin	127-136	5-hydroxytryptamine receptor 1A	Homo sapiens	61-67	
18094064-9	2008	The effects of 8-OH-DPAT were prevented after dialysis of the selective 5-HT1A receptor antagonist WAY-100635.	8-Hydroxy-2-(di-n-propylamino)tetralin	15-24	5-hydroxytryptamine receptor 1A	Homo sapiens	72-87	
18289523-1	2008	The effect of chronic citalopram or escitalopram administration on 5-HT1A receptor function in the dorsal raphe nucleus was determined by measuring [35S]GTP gamma S binding stimulated by the 5-HT1A receptor agonist (R)-(+)-8-OH-DPAT (1nM-10 microM).	8-Hydroxy-2-(di-n-propylamino)tetralin	215-232	5-hydroxytryptamine receptor 1A	Homo sapiens	191-206	
17916336-4	2007	In the current study, the effects of iontophoretic application of the 5-HT 1A agonist 8-OH-DPAT on auditory responses were compared with the characteristic frequencies (CFs), recording depths, and control first-spike latencies of the same group of IC neurons.	8-Hydroxy-2-(di-n-propylamino)tetralin	86-95	5-hydroxytryptamine receptor 1A	Homo sapiens	70-77	
17675218-7	2008	The patients with cardiovascular disease showed a reduction (-50.40%) (p<0.01) of the 3H-8OH-DPAT bound to the platelet membranes 5-HT1A receptors (1.652+/-0.79 fmol/mg protein) with respect to the control group (3.331+/-0.16 fmol/mg protein).	8-Hydroxy-2-(di-n-propylamino)tetralin	92-100	5-hydroxytryptamine receptor 1A	Homo sapiens	133-139	
17431134-5	2007	The preadministration of the 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 microg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED(50) by 56 and 44%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	55-88	5-hydroxytryptamine receptor 1A	Homo sapiens	29-46	
17663006-7	2007	NHE activity was significantly increased by 8-OH-DPAT and alpha-methyl-5-HT, agonists of, respectively, 5-HT(1A) and 5-HT(2) receptors.	8-Hydroxy-2-(di-n-propylamino)tetralin	44-53	5-hydroxytryptamine receptor 1A	Homo sapiens	104-111	
17392335-2	2007	Activation of presynaptic 5-HT(1A) receptors inhibits serotonergic neurones in the ventral medulla and caudal raphe, and we tested the hypothesis that administration of 8-hydroxydipropylaminotetralin (8-OH-DPAT), a 5-HT(1A) agonist, within the rostroventral medulla and caudal raphe would enhance baroreceptor-mediated inhibition of respiratory activity in decerebrate, neonatal piglets.	8-Hydroxy-2-(di-n-propylamino)tetralin	201-210	5-hydroxytryptamine receptor 1A	Homo sapiens	26-33	
17392335-9	2007	We conclude that activation of 5-HT(1A) receptors after systemic administration of 8-OH-DPAT enhanced baroreflex-mediated inhibition of ventilation, but this effect cannot be attributed to 5-HT(1A) receptor activation within the rostroventral medulla and caudal raphe.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	31-38	
17392335-9	2007	We conclude that activation of 5-HT(1A) receptors after systemic administration of 8-OH-DPAT enhanced baroreflex-mediated inhibition of ventilation, but this effect cannot be attributed to 5-HT(1A) receptor activation within the rostroventral medulla and caudal raphe.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	31-48	
17431134-5	2007	The preadministration of the 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT) (1 and 40 microg/kg) significantly enhanced the venlafaxine inhibitory effect, decreasing the ED(50) by 56 and 44%, respectively.	8-Hydroxy-2-(di-n-propylamino)tetralin	90-99	5-hydroxytryptamine receptor 1A	Homo sapiens	29-46	
17321680-1	2007	The 5-HT(1A) receptor agonist 8-OH-DPAT (0.5mg/kg) enhances behavioral recovery when administered 15min after experimental traumatic brain injury (TBI).	8-Hydroxy-2-(di-n-propylamino)tetralin	30-39	5-hydroxytryptamine receptor 1A	Homo sapiens	4-21	
17493597-5	2007	(+/-)-8-hydroxy-2-(di-n-propylamino)tetralin (a 5-HT1A receptor agonist, 1 and 2 mg/kg) markedly reduced paired-pulse inhibition in the CA1 region of SS adult gerbils only.	8-Hydroxy-2-(di-n-propylamino)tetralin	0-44	5-hydroxytryptamine receptor 1A	Homo sapiens	48-63	
20641465-11	2004	Selective agonists such as 8-hydroxy-N-N-dipropylaminotetralin (8-OH-DPAT) were initially studied, but because they bind to the relatively few 5-HT1A receptors in the high-affinity state, the higher affinity required in that situation was difficult to achieve (6).	8-Hydroxy-2-(di-n-propylamino)tetralin	64-73	5-hydroxytryptamine receptor 1A	Homo sapiens	143-149	
17141811-6	2007	Adaptive changes in 5-HT(1A) receptor function were studied by measuring 8-OH-DPAT-mediated hypothermia and lower lip retraction (LLR) in the animals 24h after LH test session.	8-Hydroxy-2-(di-n-propylamino)tetralin	73-82	5-hydroxytryptamine receptor 1A	Homo sapiens	20-37	
17416565-6	2007	The present study shows that responses to 8-hydroxy-2-(di-n-propylamino)tetraline (8-OH-DPAT), a selective 5-HT 1A agonist decreased following exposure to single stress and the decreases were normalized following adaptation to stress.	8-Hydroxy-2-(di-n-propylamino)tetralin	83-92	5-hydroxytryptamine receptor 1A	Homo sapiens	107-114